Anti-factor XII / XIIa antibodies and uses thereof
By developing antibodies and antigen-binding fragments specifically binding to activated form of coagulation factor XII, the problem of existing anticoagulants increasing bleeding risk is solved, and effective prevention of thrombosis and endogenous pathways without increasing bleeding risk is achieved. Caused coagulation and inflammation.
Patent Information
- Application Number
- CN201980046743.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-06-19
- Filing Date
- 2019-06-19
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2039-06-19
AI Technical Summary
Existing anticoagulants tend to increase bleeding risk when inhibiting thrombosis and are difficult to effectively prevent coagulation and inflammation caused by endogenous pathways.
Develop high-affinity antibodies and antigen-binding fragments specifically bound to the activated form of coagulation factor XII (FXIIa) to inhibit FXII activity, prevent and treat related diseases, while preventing thrombosis without increasing risk of bleeding.
It achieves effective prevention of thrombosis without increasing the risk of bleeding, inhibiting coagulation and inflammation caused by endogenous pathways, providing a new anticoagulant therapy that can be used at lower doses and frequency.
Smart Images

Figure BDA0002894291080000311 
Figure BDA0002894291080000312 
Figure BDA0002894291080000323
Abstract
Description
[0001] Related Applications
[0002] The present invention claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 687,144, filed on June 19, 2018, the entire contents of which are incorporated herein by reference.
[0003] Sequence Listing
[0004] This application contains a sequence listing, which has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy created on June 18, 2019 is named 10463WO01_SL.txt and is 26,288 bytes in size. Technical Field
[0005] The present invention relates to antibodies and antibody antigen-binding fragments that specifically bind to coagulation factor XII, and therapeutic and diagnostic methods using those antibodies. Background Art
[0006] Coagulation factors and platelets are blood components related in the hemostasis process during vascular injury. It is recognized that when regulation (i.e., production and / or activity) is unbalanced, these components can be drivers of thrombosis. Thrombotic diseases are believed to be mainly caused by abnormal activation (via tissue factor) in exogenous pathways, but recently, preclinical studies using F12-deficient mice and molecules targeting activation of FXII (FXIIa) have shown that the endogenous pathway of coagulation (also referred to as the contact pathway) is also involved (Renne et al., 2005, Journal of Experimental Medicine (J. Exp. Med.), 202: 271-81; Larsson et al., 2014, Sci. Transl. Med. 6: 222ra17). FXIIa is essential for the contact pathway and can drive coagulation via the cleavage of FXI or can drive inflammation via the cleavage of plasma kallikrein. Therefore, inhibition of FXII activity can lead to a reduction in thrombotic coagulation and inflammation associated with contact pathway activation (Schousboe 2007, Biochem. Pharmacol. 75: 1007-13; Danese et al. 2016, Semin. Thromb. Hemostat. 42: 682-8; Weitz 2016, Thromb. Res. 141 Suppl. 2: S40-5). Anticoagulants currently used in the art (e.g., heparin) are effective antithrombotic agents, but they also increase the risk of bleeding. Therefore, there is a need to develop anticoagulants that prevent thrombosis without increasing the risk of bleeding.
[0007] Monoclonal antibodies to FXII are known in the art and have been described in, e.g., U.S. Patent / Publication Nos. 4,963,657, 5,500,349, 8,119,137, 8,715,672, 9,856,326, 9,856,325, 9,518,127, 20130095108, 20140072572, 20140072600, and WO2006066878, WO2013014092, EP1830924B1, EP27345522A1, and EP2623110A1.
[0008] Fully human antibodies that specifically bind to (activated) FXII protein with high affinity and prevent thrombosis without increasing the risk of bleeding may be important in preventing and treating various FXII-related diseases (e.g., thrombosis, embolism, edema). Summary of the invention
[0009] The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to the activated form (FXIIa) of coagulation factor XII protein. In certain embodiments, the antibody also binds to the zymogen form (FXII) of factor XII. In certain embodiments, the antibody is a fully human antibody ("double FXII / FXIIa conjugate") that binds to FXII with high affinity and also binds to FXIIa. The antibody of the present invention is particularly suitable for inhibiting or neutralizing the activity of FXII protein. In certain embodiments, the antibody is suitable for preventing, treating or improving at least one symptom or sign of FXII-related diseases or conditions in a subject. In certain embodiments, the antibody can be given prophylactically or therapeutically to a subject suffering from FXII-related diseases or conditions or at risk of suffering from FXII-related diseases or conditions. In certain preferred embodiments. In a specific embodiment, the antibody prevents thrombosis without increasing the risk of bleeding in the subject. Such antibodies can be given to a subject in need in the form of anticoagulant therapy without increasing the risk of bleeding, and in a subject suffering from FXII-related diseases or conditions with fewer administrations.
[0010] The antibodies of the present invention may be full length (e.g., IgG1 or IgG4 antibodies) or may contain only an antigen binding portion (e.g., Fab, F(ab')2, or scFv fragments), and may be modified to affect functionality, such as increasing persistence in the host or eliminating residual effector functions (Reddy et al., 2000, J. Immunol. 164: 1925-1933). In certain embodiments, the antibodies may be bispecific.
[0011] In a first aspect, the present invention provides an isolated recombinant monoclonal antibody or an antigen-binding fragment thereof that specifically binds to factor XII (FXII) and / or activated factor XII (FXIIa). In some embodiments, the antibody is a fully human monoclonal antibody. In certain embodiments, the antibody is a "dual binder" that is capable of binding to FXII and FXIIa.
[0012] Exemplary anti-FXII / FXIIa antibodies of the invention are listed in Tables 1 and 2 herein. Table 1 lists the amino acid sequence identifiers of the heavy chain variable region (HCVR), light chain variable region (LCVR), heavy chain complementarity determining region (HCDR) (HCDR1, HCDR2 and HCDR3) and light chain complementarity determining region (LCDR) (LCDR1, LCDR2 and LCDR3) of exemplary antibodies. Table 2 lists the nucleic acid sequence identifiers of the HCVR, LCVR, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of exemplary antibodies.
[0013] The present invention provides an antibody or antigen-binding fragment thereof comprising a HCVR comprising an amino acid sequence selected from any of the HCVR amino acid sequences listed in Table 1 or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
[0014] The present invention also provides an antibody or antigen-binding fragment thereof comprising a LCVR comprising an amino acid sequence selected from any of the LCVR amino acid sequences listed in Table 1 or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
[0015] The present invention also provides antibodies or antigen-binding fragments thereof comprising a HCVR and LCVR amino acid sequence pair (HCVR / LCVR), wherein the amino acid sequence pair comprises a pair of any HCVR amino acid sequence listed in Table 1 and any LCVR amino acid sequence listed in Table 1. According to certain embodiments, the present invention provides antibodies or antigen-binding fragments thereof, comprising a HCVR / LCVR amino acid sequence pair contained in any exemplary anti-FXII / FXIIa antibody listed in Table 1. In certain embodiments, the HCVR / LCVR amino acid sequence pair is selected from one of SEQ ID NO: 2 / 10 (e.g., mAb26036), 18 / 26 (e.g., mAb26048), 34 / 42 (e.g., mAb26049), or 50 / 58 (e.g., mAb26076).
[0016] The present invention also provides antibodies or antigen-binding fragments thereof comprising a HCVR and a LCVR, wherein the HCVR comprises an amino acid sequence listed in Table 1 with no more than twelve amino acid substitutions, and / or the LCVR comprises an amino acid sequence listed in Table 1 with no more than ten amino acid substitutions. For example, the present invention provides antibodies or antigen-binding fragments thereof comprising a HCVR and a LCVR, wherein the HCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50, wherein the amino acid sequence has one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve amino acid substitutions. In another example, the present invention provides antibodies or antigen-binding fragments thereof comprising a HCVR and a LCVR, wherein the LCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, and 58, wherein the amino acid sequence has one, two, three, four, five, six, seven, eight, nine, or ten amino acid substitutions. In one embodiment, the present invention provides an anti-FXII / FXIIa antibody or antigen-binding fragment thereof comprising a HCVR and a LCVR, wherein the HCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34 and 50, wherein the amino acid sequence has at least one amino acid substitution, and / or the LCVR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42 and 58, wherein the amino acid sequence has at least one amino acid substitution.
[0017] The present invention also provides an antibody or an antigen-binding fragment thereof comprising a heavy chain CDR1 (HCDR1), wherein the heavy chain CDR1 comprises an amino acid sequence selected from any HCDR1 amino acid sequence listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0018] The present invention also provides an antibody or antigen-binding fragment thereof comprising a heavy chain CDR2 (HCDR2), wherein the heavy chain CDR2 comprises an amino acid sequence selected from any HCDR2 amino acid sequence listed in Table 1 or a substantially similar sequence thereof having a sequence identity of at least 90%, at least 95%, at least 98% or at least 99%.
[0019] The present invention also provides an antibody or antigen-binding fragment thereof comprising a heavy chain CDR3 (HCDR3), wherein the heavy chain CDR3 comprises an amino acid sequence selected from any HCDR3 amino acid sequence listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0020] The present invention also provides an antibody or an antigen-binding fragment thereof comprising a light chain CDR1 (LCDR1), wherein the light chain CDR1 comprises an amino acid sequence selected from any LCDR1 amino acid sequence listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0021] The present invention also provides an antibody or an antigen-binding fragment thereof comprising a light chain CDR2 (LCDR2), wherein the light chain CDR2 comprises an amino acid sequence selected from any LCDR2 amino acid sequence listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0022] The present invention also provides an antibody or an antigen-binding fragment thereof comprising a light chain CDR3 (LCDR3), wherein the light chain CDR3 comprises an amino acid sequence selected from any LCDR3 amino acid sequence listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.
[0023] The present invention also provides antibodies or antigen-binding fragments thereof comprising a HCDR3 and LCDR3 amino acid sequence pair (HCDR3 / LCDR3), wherein the amino acid sequence pair comprises a pairing of any HCDR3 amino acid sequence listed in Table 1 with any LCDR3 amino acid sequence listed in Table 1. According to certain embodiments, the present invention provides antibodies or antigen-binding fragments thereof, comprising a HCDR3 / LCDR3 amino acid sequence pair contained in any exemplary anti-FXII antibody listed in Table 1. In certain embodiments, the HCDR3 / LCDR3 amino acid sequence pair is selected from the group consisting of: SEQ ID NO: 8 / 16 (e.g., mAb26036), 24 / 32 (e.g., mAb26048), 40 / 48 (e.g., mAb26049), and 56 / 64 (e.g., mAb26076).
[0024] The present invention also provides an antibody or antigen-binding fragment thereof comprising a HCVR and a LCVR, wherein the HCVR comprises a HCDR1 comprising an amino acid sequence that differs by 1 amino acid from the amino acid sequence listed in Table 1; a HCDR2 comprising an amino acid sequence that differs by 1 amino acid from the amino acid sequence listed in Table 1; and a HCDR3 comprising an amino acid sequence that differs by 1 amino acid from the amino acid sequence listed in Table 1. In certain embodiments, the present invention provides an antibody or antigen-binding fragment thereof comprising a HCVR and a LCVR, wherein the LCVR comprises a LCDR1 comprising an amino acid sequence that differs by 1 amino acid from the amino acid sequence listed in Table 1; a LCDR2 comprising an amino acid sequence that differs by 1 amino acid from the amino acid sequence listed in Table 1; and a LCDR3 comprising an amino acid sequence that differs by 1 amino acid from the amino acid sequence listed in Table 1. For example, the present invention provides an antibody or antigen-binding fragment thereof comprising a HCVR and a LCVR, wherein the HCVR comprises a HCDR1 comprising an amino acid sequence of SEQ ID NO: 4 or an amino acid sequence differing from SEQ ID NO: 4 by 1 amino acid, a HCDR2 comprising an amino acid sequence of SEQ ID NO: 6 or an amino acid sequence differing from SEQ ID NO: 6 by 1 amino acid, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 8 or an amino acid sequence differing from SEQ ID NO: 8 by 1 amino acid. In another exemplary embodiment, the present invention provides an antibody or antigen-binding fragment thereof comprising a HCVR and a LCVR, wherein the LCVR comprises a LCDR1 comprising an amino acid sequence of SEQ ID NO: 12 or an amino acid sequence differing from SEQ ID NO: 12 by 1 amino acid, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 14 or an amino acid sequence differing from SEQ ID NO: 14 by 1 amino acid, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 16 or an amino acid sequence differing from SEQ ID NO: 16 by 1 amino acid.
[0025] The present invention also provides antibodies or antigen-binding fragments thereof comprising a set of six CDRs (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained in any of the exemplary antibodies listed in Table 1. In certain embodiments, the HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence set is selected from the group consisting of: SEQ ID NO: 4-6-8-12-14-16 (e.g., mAb26036), 20-22-24-28-30-32 (e.g., mAb26048), 36-38-40-44-46-48 (e.g., mAb26049), and 52-54-56-60-62-64 (e.g., mAb26076).
[0026] In a related embodiment, the present invention provides an antibody or antigen-binding fragment thereof comprising a set of six CDRs (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained within a HCVR / LCVR amino acid sequence pair defined by any of the exemplary antibodies listed in Table 1. For example, the present invention includes an antibody or antigen-binding fragment thereof comprising a set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences contained within a HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NO: 2 / 10 (e.g., mAb26036), 18 / 26 (e.g., mAb26048), 34 / 42 (e.g., mAb26049), or 50 / 58 (e.g., mAb26076). Methods and techniques for identifying CDRs within HCVR and LCVR amino acid sequences are well known in the art and can be used to identify CDRs within the specified HCVR and / or LCVR amino acid sequences disclosed herein. Exemplary conventions that can be used to identify CDR boundaries include, for example, Kabat definition, Chothia definition, and AbM definition. In general, Kabat definition is based on sequence variation, Chothia definition is based on the position of each structural loop region, and AbM definition is a compromise between Kabat method and Chothia method. See, for example, Kabat, "Sequences of Proteins of Immunological Interest", National Institutes of Health, Bethesda, Maryland (1991); Al-Lazikani et al., "Journal of Molecular Biology (J.Mol.Biol.)" 273:927-948 (1997); and Martin et al., "Proc.Natl.Acad.Sci.USA" 86:9268-9272 (1989). Public databases can also be used to identify CDR sequences within antibodies.
[0027] In certain embodiments, the present invention includes an antibody or antigen-binding fragment thereof that specifically binds to FXII and / or FXIIa, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within a light chain variable region (LCVR), wherein the HCVR comprises: (i) an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50, (ii) an amino acid sequence having at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50, (iii) an amino acid sequence having at least 95% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50; or (iv) an amino acid sequence having no more than 12 amino acid substitutions selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50; and the LCVR comprises: (i) an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, and 50. NO:10, 26, 42 and 58, (ii) an amino acid sequence having at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NO:10, 26, 42 and 58, (iii) an amino acid sequence having at least 95% identity to an amino acid sequence selected from the group consisting of SEQ ID NO:10, 26, 42 and 58; or (iv) an amino acid sequence having no more than 10 amino acid substitutions selected from the group consisting of SEQ ID NO:10, 26, 42 and 58.
[0028] The present invention includes anti-FXII / FXIIa antibodies with modified glycosylation patterns. In some embodiments, modifications to remove undesirable glycosylation sites may be useful, or antibodies lacking fucose moieties present on oligosaccharide chains, for example, enhance antibody-dependent cellular cytotoxicity (ADCC) function (see Shield et al. (2002) JBC 277:26733). In other applications, modifications of galactosylation may be performed to modify complement-dependent cytotoxicity (CDC).
[0029] In certain embodiments, the present invention provides antibodies and antigen-binding fragments thereof that exhibit binding to FXII in a pH-dependent manner. For example, the present invention includes antibodies and antigen-binding fragments thereof that bind to FXII with a higher affinity at neutral pH than at acidic pH (i.e., binding is reduced at acidic pH).
[0030] The present invention also provides antibodies and antigen-binding fragments thereof that compete with antibodies or antigen-binding fragments thereof for specific binding to FXII or FXIIa comprising the CDRs of the HCVR and the CDRs of the LCVR, wherein the HCVR and LCVR each have an amino acid sequence selected from the HCVR and LCVR sequences listed in Table 1.
[0031] The present invention also provides antibodies and antigen-binding fragments thereof that cross-compete with a reference antibody or antigen-binding fragment thereof comprising the CDRs of a HCVR and the CDRs of a LCVR for binding to FXII or FXIIa, wherein the HCVR and LCVR each have an amino acid sequence selected from the HCVR and LCVR sequences listed in Table 1.
[0032] The present invention also provides antibodies and antigen-binding fragments thereof that bind to the same epitope as a reference antibody or antigen-binding fragment thereof, wherein the reference antibody or antigen-binding fragment thereof comprises three CDRs of a HCVR and three CDRs of a LCVR, wherein the HCVR and LCVR each have an amino acid sequence selected from the HCVR and LCVR sequences listed in Table 1.
[0033] In some embodiments, the antibody or antigen-binding fragment thereof can specifically bind to FXII and / or FXIIa in an agonist manner, i.e., it can enhance or stimulate FXII / FXIIa binding and / or activity; in other embodiments, the antibody can specifically bind to FXII and / or FXIIa in an antagonist manner, i.e., it can block FXII binding and / or activity.
[0034] The present invention also provides isolated antibodies and antigen-binding fragments thereof that block FXIIa from binding to FXI. In some embodiments, the antibody or antigen-binding fragment thereof that blocks FXIIa from binding to FXI can bind to the same epitope on FXIIa as FXI or can bind to a different epitope on FXIIa than FXI.
[0035] In certain embodiments, the antibodies or antigen-binding fragments of the invention are bispecific, comprising a first binding specificity for a first epitope of FXII / FXIIa and a second binding specificity for a second epitope of FXII / FXIIa, wherein the first and second epitopes are different and non-overlapping.
[0036] In certain embodiments, the present invention provides an isolated antibody or antigen-binding fragment thereof having one or more of the following characteristics: (a) being a fully human monoclonal antibody; (b) binding to activated factor XII (FXIIa); (c) dissociating with a dissociation constant (K) of less than 3.5 nM at 25° C. as measured in a surface plasmon resonance assay; D) binds to FXII with a K of less than 17 nM at 37°C as measured in a surface plasmon resonance assay; (d) binds to FXII with a K of less than 17 nM at 37°C D (e) binds to FXII with a K of less than 5 nM, preferably less than 2.5 nM at 25°C as measured in a surface plasmon resonance assay; D (f) binds to FXIIa with a K of less than 6.5 nM, preferably less than 2.5 nM at 37°C as measured in a surface plasmon resonance assay; D (g) blocks thrombin generation by the intrinsic pathway at a concentration of less than 250 nM as measured by a functional plasma assay; and (h) blocks thrombin generation by the intrinsic pathway without blocking thrombin generation by the extrinsic pathway as measured by a functional plasma assay.
[0037] In a second aspect, the present invention provides nucleic acid molecules encoding anti-FXII / FXIIa antibodies or portions thereof. For example, the present invention provides nucleic acid molecules encoding any HCVR amino acid sequence listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any HCVR nucleic acid sequence listed in Table 2 or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
[0038] The present invention also provides nucleic acid molecules encoding any of the LCVR amino acid sequences listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 2 or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
[0039] The present invention also provides a nucleic acid molecule encoding any HCDR1 amino acid sequence listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any HCDR1 nucleic acid sequence listed in Table 2 or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
[0040] The present invention also provides a nucleic acid molecule encoding any HCDR2 amino acid sequence listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any HCDR2 nucleic acid sequence listed in Table 2 or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
[0041] The present invention also provides a nucleic acid molecule encoding any HCDR3 amino acid sequence listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any HCDR3 nucleic acid sequence listed in Table 2 or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
[0042] The present invention also provides nucleic acid molecules encoding any LCDR1 amino acid sequence listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any LCDR1 nucleic acid sequence listed in Table 2 or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
[0043] The present invention also provides nucleic acid molecules encoding any LCDR2 amino acid sequence listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any LCDR2 nucleic acid sequence listed in Table 2 or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
[0044] The present invention also provides nucleic acid molecules encoding any LCDR3 amino acid sequence listed in Table 1; in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any LCDR3 nucleic acid sequence listed in Table 2 or a substantially similar sequence having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.
[0045] The present invention also provides a nucleic acid molecule encoding a HCVR, wherein the HCVR comprises a set of three CDRs (ie, HCDR1-HCDR2-HCDR3), wherein the HCDR1-HCDR2-HCDR3 amino acid sequence set is as defined by any of the exemplary antibodies listed in Table 1.
[0046] The present invention also provides nucleic acid molecules encoding LCVRs, wherein the LCVR comprises a set of three CDRs (ie, LCDR1-LCDR2-LCDR3), wherein the LCDR1-LCDR2-LCDR3 amino acid sequence set is as defined by any of the exemplary antibodies listed in Table 1.
[0047] The present invention also provides nucleic acid molecules encoding both HCVR and LCVR, wherein the HCVR comprises an amino acid sequence of any HCVR amino acid sequence listed in Table 1, and wherein the LCVR comprises an amino acid sequence of any LCVR amino acid sequence listed in Table 1. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any HCVR nucleic acid sequence listed in Table 2, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto, and a polynucleotide sequence selected from any LCVR nucleic acid sequence listed in Table 1, or a substantially similar sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto. In certain embodiments according to this aspect of the invention, the nucleic acid molecule encodes a HCVR and a LCVR, wherein both the HCVR and the LCVR are derived from the same anti-FXII antibody listed in Table 1.
[0048] In a related aspect, the present invention provides a recombinant expression vector capable of expressing a polypeptide comprising a heavy chain or light chain variable region of an antibody. For example, the present invention includes a recombinant expression vector comprising any of the nucleic acid molecules mentioned above, i.e., a nucleic acid molecule encoding any of the HCVR, LCVR and / or CDR sequences listed in Table 2. In certain embodiments, the present invention provides an expression vector comprising: (a) a nucleic acid molecule comprising a nucleic acid sequence encoding an antibody HCVR, the antibody binds FXII / FXIIa, wherein the HCVR comprises an amino acid sequence selected from the group consisting of the sequences listed in Table 1; and / or (b) a nucleic acid molecule comprising a nucleic acid sequence encoding an antibody LCVR, the antibody binds FXII / FXIIa, wherein the LCVR comprises an amino acid sequence selected from the group consisting of the sequences listed in Table 1. Also included within the scope of the present invention are host cells into which such vectors have been introduced, and methods of producing the antibody or portion thereof by culturing the host cell under conditions that allow the production of the antibody or antibody fragment, and recovering the antibody and antibody fragment so produced. In certain embodiments, the host cell comprises a mammalian cell or a prokaryotic cell. In certain embodiments, the host cell is a Chinese hamster ovary (CHO) cell or an Escherichia coli (E. coli) cell. In certain embodiments, the present invention provides a method for producing an antibody or antigen-binding fragment thereof of the present invention, the method comprising introducing an expression vector comprising a nucleic acid sequence encoding the HCVR and / or LCVR of the antibody or antigen-binding fragment thereof into a host cell, the antibody or antigen-binding fragment thereof being operably linked to a promoter; culturing the host cell under conditions conducive to expression of the nucleic acid sequence; and isolating the antibody or antigen-binding fragment thereof from the culture medium and / or the host cell. The isolated antibody or antigen-binding fragment thereof can be purified using any method known in the art.
[0049] In a third aspect, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of at least one recombinant monoclonal antibody or antigen-binding fragment thereof that specifically binds to FXII / FXIIa and a pharmaceutically acceptable carrier. In a related aspect, the present invention features a composition that is a combination of an anti-FXII / FXIIa antibody and a second therapeutic agent. In one embodiment, the second therapeutic agent is any agent that is advantageously combined with an anti-FXII / FXIIa antibody. Exemplary agents that may be advantageously combined with anti-FXII / FXIIa antibodies include, but are not limited to, other agents that bind to and / or inhibit FXII activity (including other antibodies or antigen-binding fragments thereof, etc.) and / or agents that do not directly bind to FXII but still treat or improve at least one symptom or sign of a FXII-related disease or condition. Additional combination therapies and co-formulations involving anti-FXII antibodies of the present invention are disclosed elsewhere herein.
[0050] In a fourth aspect, the present invention provides a method of treating a disease or condition associated with FXII in a subject using an anti-FXII / FXIIa antibody or an antibody antigen-binding portion of the present invention, wherein the method of treating comprises administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising the antibody and antibody antigen-binding fragment of the present invention. The condition treated is any disease or condition that is improved, alleviated, inhibited or prevented by inhibiting FXII activity. In certain embodiments, the present invention provides a method of preventing a FXII-related disease or condition, or treating a FXII-related disease or condition, comprising administering to a subject in need thereof an effective amount of an anti-FXII / FXIIa antibody or an antigen-binding fragment thereof of the present invention. In some embodiments, the antibody or its antigen-binding fragment may be administered prophylactically or therapeutically to a subject suffering from a FXII-related disease or condition or at risk of suffering from a FXII-related disease or condition. In certain embodiments, the antibody or its antigen-binding fragment of the present invention is administered in combination with a second therapeutic agent to the subject in need thereof. The second therapeutic agent can be selected from the group consisting of: anticoagulants, direct thrombin inhibitors, thrombolytic drugs, fibrinolytic drugs, antiplatelet drugs, anti-inflammatory drugs, antihypertensive drugs, second anti-FXII antibodies, lipid-lowering drugs, mechanical clot retrieval, catheter-guided thrombolysis, compression stockings, surgery, and any other drugs or therapies known in the art. In certain embodiments, if any possible side effects associated with the antibody or antigen-binding fragment thereof of the present invention occur, the second therapeutic agent can be an agent that helps to offset or reduce such side effects. The antibody or its fragment can be administered subcutaneously, intravenously, intradermally, intraperitoneally, orally or intramuscularly. The antibody or its fragment can be administered at a dose of about 0.1 mg / kg to about 100 mg / kg of the subject's body weight. In certain embodiments, the antibody of the present invention can be administered at one or more doses contained between 10 mg and 600 mg.
[0051] The present invention also includes the use of an anti-FXII / FXIIa antibody or antigen-binding fragment thereof of the present invention in the manufacture of a medicament for treating a disease or condition that would benefit from blocking FXII / FXIIa binding and / or activity.
[0052] Other embodiments will become apparent by reviewing the following detailed description. DETAILED DESCRIPTION
[0053] Before describing the method of the present invention, it should be understood that the present invention is not limited to the specific method and described experimental conditions, and thus the method and conditions can vary. It should also be understood that the terms used herein are only for the purpose of describing specific embodiments, and are not intended to be restrictive, because the scope of the present invention will only be limited by the appended claims.
[0054] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to the methods and materials described herein can be used in the practice or testing of the present invention, preferred methods and materials are now described. All disclosures mentioned herein are incorporated herein by reference in their entirety.
[0055] definition
[0056] The term "FXII", also known as "factor XII", refers to coagulation factor XII, also known as Hageman Factor. The 596-amino acid FXII protein is an enzyme form of factor XIIa, i.e., a β-plasma globulin serine proteinase consisting of an amino-terminal heavy chain and a carboxyl-terminal light chain. Its heavy chain contains two fiber-binding protein-like domains (types I and II), two epidermal growth factor-like domains, a three-ring domain (Kringle domain) and a proline-rich region, and its light chain contains a protein enzyme domain. Blood is exposed to negatively charged substances or artificial surfaces via a series of reactions known as contact activation to trigger thrombin generation and fibrin formation. Factor XII activates factor XI and prekallikrein in the coagulation cascade. Factor XII itself is activated as factor XIIa by plasma prekallikrein, platelet or bacterial polyphosphates, extracellular DNA or RNA, heparin released from mast cells, amyloid protein peptides, misfolded protein aggregates, and negatively charged surfaces (such as glass). This is the starting point of the endogenous pathway. The amino acid sequence of the full-length FXII protein is exemplified by the amino acid sequence provided in UniProtKB / Swiss-Prot with the accession number P00748.3. The amino acid sequence of the full-length FXII protein is also shown herein as SEQ ID NO:65. The term "FXII" includes recombinant FXII protein or fragments thereof. The term also encompasses FXII protein or fragments thereof coupled to, for example, a histidine tag, mouse or human Fc, or a signal sequence such as ROR1.
[0057] As used herein, the term "antibody" is intended to refer to an immunoglobulin molecule composed of four polypeptide chains, i.e., two heavy (H) chains and two light (L) chains interconnected by disulfide bonds (i.e., a "complete antibody molecule"); as well as multimers thereof (e.g., IgM), or antigen-binding fragments thereof. Each heavy chain consists of a heavy chain variable region ("HCVR" or "V H ”) and the heavy chain constant region (composed of domain C H 1. C H 2 and C H Each light chain consists of a light chain variable region ("LCVR" or "V L ”) and the light chain constant region (C L ) H and V L The V region can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). H and V L It is composed of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In certain embodiments of the present invention, the FRs of the antibody (or its antigen-binding fragment) may be consistent with the human germline sequence, or may be modified naturally or artificially. The amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.
[0058] It is also possible to replace one or more CDR residues or omit one or more CDRs. Antibodies have been described in the scientific literature, in which one or two CDRs can be assigned for binding. Padlan et al. (1995 "Journal of the Federation of American Societies for Experimental Biology (FASEB J.)" 9:133-139) analyzed the contact area between the antibody and its antigen based on the disclosed crystal structure, and concluded that only about one-fifth to one-third of the CDR residues actually contact the antigen. Padlan also found many antibodies in which one or two CDRs have no amino acids in contact with the antigen (see also Vajdos et al., 2002 "Journal of Molecular Biology" 320:415-428).
[0059] Based on previous studies, CDR residues that do not contact antigen can be identified from the Kabat CDR region outside the Cosia CDR by molecular modeling and / or empirically (e.g., residues H60-H65 in CDRH2 are generally not required). If a CDR or its residues are omitted, they are generally replaced by amino acids occupying corresponding positions in another human antibody sequence or a common sequence of such sequences. The position of the substitution within the CDR and the amino acid for substitution can also be selected empirically. Empirical substitutions can be conservative or non-conservative substitutions.
[0060] The fully human anti-FXII monoclonal antibodies disclosed herein may comprise one or more amino acid substitutions, insertions and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains compared to the corresponding germline sequences. Such mutations can be easily determined by comparing the amino acid sequences disclosed herein with germline sequences obtained from, for example, public antibody sequence databases. The present invention includes antibodies and antigen-binding fragments thereof derived from any amino acid sequence disclosed herein, wherein one or more amino acids within one or more framework and / or CDR regions are mutated to the corresponding residues of the germline sequence from which the antibody is derived, or the corresponding residues of another human germline sequence, or conservative amino acid substitutions of the corresponding germline residues (such sequence changes are collectively referred to herein as "germline mutations"). Starting from the heavy and light chain variable region sequences disclosed herein, one of ordinary skill in the art can easily generate many antibodies and antigen-binding fragments comprising one or more individual germline mutations or combinations thereof. In certain embodiments, V H and / or V L All frameworks and / or CDR residues in the domain are mutated back to the residues found in the original germline sequence of the antibody derived. In other embodiments, only some residues are mutated back to the original germline sequence, for example, only the mutated residues found in the first 8 amino acids of FR1 or in the last 8 amino acids of FR4, or only the mutated residues found in CDR1, CDR2 or CDR3. In other embodiments, one or more mutations in framework and / or CDR residues are mutated to the corresponding residues of different germline sequences (that is, germline sequences different from the germline sequences of the antibody initially derived). In addition, the antibody of the present invention can contain any combination of two or more germline mutations in framework and / or CDR regions, for example, wherein some individual residues are mutated to the corresponding residues of specific germline sequences, and some other residues different from the original germline sequence can maintain or mutate to the corresponding residues of different germline sequences. Once obtained, antibodies and antigen-binding fragments containing one or more germline mutations can be readily tested for one or more desired properties, such as improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc. Antibodies and antigen-binding fragments obtained in this general manner are encompassed by the present invention.
[0061] The present invention also includes fully human anti-FXII monoclonal antibodies comprising variants of any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein having one or more conservative substitutions. For example, the present invention includes anti-FXII antibodies having HCVR, LCVR and / or CDR amino acid sequences having, for example, 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc., conservative amino acid substitutions relative to any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein.
[0062] As used herein, the term "human antibody" is intended to include antibodies with variable regions and constant regions derived from human germline immunoglobulin sequences. Human mAbs of the present invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or somatic mutations in vivo), such as in CDR and particularly in CDR3. However, as used herein, the term "human antibody" is not intended to include mAbs that have been transplanted to human FR sequences from CDR sequences derived from another mammalian species (e.g., mouse) germline. The term is included in antibodies produced in a recombinant manner in non-human mammals or in cells of non-human mammals. The term is not intended to include antibodies separated from human subjects or generated in human subjects.
[0063] As used herein, the term "recombinant" refers to an antibody or antigen-binding fragment thereof of the invention created, expressed, isolated or obtained by a technique or method known in the art as recombinant DNA technology, including, for example, DNA splicing and transgenic expression. The term refers to antibodies expressed in a non-human mammal (including a transgenic non-human mammal, such as a transgenic mouse), or cell (e.g., CHO cell) expression system, or antibodies isolated from a recombinant combinatorial human antibody library.
[0064] The term "specific binding" or "specifically binds to" and the like means that the antibody or antigen-binding fragment thereof forms a complex with the antigen that is relatively stable under physiological conditions. Specific binding can be achieved by at least about 1×10 -8 M or lower equilibrium dissociation constants (e.g., smaller K D Indicating tighter binding). Methods for determining whether two molecules specifically bind are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, etc. As described herein, antibodies have been identified by surface plasmon resonance (e.g., BIACORE TM) identification, the antibody specifically binds to FXII. In addition, as used herein, a multispecific antibody that binds to one domain in FXII and one or more additional antigens or bispecific antibodies that bind to two different regions of FXII are still considered to be "specifically binding" antibodies.
[0065] For example, surface plasmon resonance (e.g. BIACORE TM ) or solution affinity ELISA, the term "high affinity" antibody refers to an antibody with a K expressed as D At least 10 -8 M, preferably 10 -9 M, more preferably 10 -10 M, even more preferably 10 -11 Those mAbs with binding affinity to M.
[0066] The term "slow off rate", "Koff" or "kd" means the rate of dissociation as measured by surface plasmon resonance (e.g., BIACORE TM ) was measured with 1×10 -3 s -1 or lower, preferably 1×10 -4 s -1 The antibody dissociates from FXII with a rate constant of 1:1 or lower.
[0067] As used herein, the terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, and the like include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. As used herein, the terms "antigen-binding fragment" of an antibody or "antibody fragment" refer to one or more fragments of an antibody that retain the ability to bind to a FXII protein.
[0068] In certain embodiments, the antibodies or antibody fragments of the invention may be conjugated to a moiety, such as a ligand or therapeutic moiety ("immunoconjugate"), a second anti-FXII antibody, or any other therapeutic moiety useful for treating a FXII-related disease or disorder.
[0069] As used herein, an "isolated antibody" is intended to refer to an antibody that is substantially free of other antibodies (Abs) having different antigenic specificities (e.g., an isolated antibody that specifically binds to FXII and / or FXIIa, or a fragment thereof, is substantially free of Abs that specifically bind to antigens other than FXII or FXIIa).
[0070] As used herein, "blocking antibody" or "neutralizing antibody" (or "antibody that neutralizes FXII activity" or "antagonist antibody") is intended to refer to an antibody that binds to FXII / FXIIa resulting in inhibition of at least one biological activity of FXII. For example, the antibodies of the invention can prevent or block coagulation caused by the intrinsic pathway.
[0071] As used herein, the term "surface plasmon resonance" refers to an optical phenomenon that allows for the detection of surface plasmon resonance by, for example, using BIACORE TM The ELISA system (Uppsala, Sweden and Pharmacia Biosensor AB, Piscataway, NJ) detects changes in protein concentration within a biosensor matrix to analyze biomolecular interactions in real time.
[0072] As used herein, the term "K D ” is intended to refer to the equilibrium dissociation constant for a specific antibody-antigen interaction.
[0073] The term "epitope" refers to an antigenic determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule, called a paratope. A single antigen may have more than one epitope. Therefore, different antibodies may bind to different regions on an antigen and may have different biological effects. The term "epitope" also refers to a site on an antigen where B cells and / or T cells react. It also refers to an antigenic region to which an antibody binds. An epitope may be defined as structural or functional. A functional epitope is generally a subset of a structural epitope and has those residues that directly contribute to the affinity of the interaction. An epitope may also be conformational, i.e., composed of nonlinear amino acids. In certain embodiments, an epitope may include a determinant as a chemically active surface group of a molecule (such as an amino acid, a sugar side chain, a phosphoryl group, or a sulfonyl group), and in certain embodiments, may have a specific three-dimensional structural feature and / or a specific charge feature.
[0074] As used herein, the term "cross competition" means that an antibody or its antigen binding fragment binds to an antigen and inhibits or blocks the binding of another antibody or its antigen binding fragment. The term also includes competition between two antibodies in two directions, i.e., the first antibody binds and blocks the binding of the second antibody, and vice versa. In certain embodiments, the first antibody and the second antibody can be bound to the same epitope. Alternatively, the first antibody and the second antibody can be bound to different but overlapping epitopes, so that the binding of one of them, for example, inhibits or blocks the binding of the second antibody via steric hindrance. The cross competition between antibodies can be measured by methods known in the art, such as by real-time label-free biolayer interferometry analysis. The cross competition between two antibodies can be expressed as the binding rate of the second antibody less than the background signal due to self-self binding (wherein the first antibody and the second antibody are the same antibody). The cross competition between 2 antibodies can be expressed, for example, as the binding % of the second antibody less than the baseline self-self background binding (wherein the first antibody and the second antibody are the same antibody).
[0075] The terms "substantially identical" or "substantially identical" when referring to a nucleic acid or a fragment thereof indicate that the nucleotide sequence identity is at least about 90% of the nucleotide bases when optimally aligned with another nucleic acid (or its complementary strand) with appropriate nucleotide insertions or deletions, and more preferably, at least about 95%, 96%, 97%, 98% or 99%, as discussed below, as measured by any well-known sequence identity algorithm such as FASTA, BLAST or GAP. In some cases, a nucleic acid molecule having substantial identity to a reference nucleic acid molecule can encode a polypeptide having an identical or substantially similar amino acid sequence to a polypeptide encoded by the reference nucleic acid molecule.
[0076] When applied to polypeptides, the term "substantially similar" or "substantially similar" means that two peptide sequences have at least 90% sequence identity, even more preferably at least 95%, 98% or 99% sequence identity, when optimally aligned, such as by using the program GAP or BESTFIT with default gap weights. Preferably, the inconsistent residue positions differ due to conservative amino acid substitutions. "Conservative amino acid substitutions" are amino acid substitutions in which an amino acid residue is substituted by another amino acid residue having similar chemical properties (e.g., charge or hydrophobicity) by a side chain (R group). In general, conservative amino acid substitutions do not substantially change the functional properties of a protein. In the case where two or more amino acid sequences differ from each other due to conservative substitutions, the percentage or degree of similarity can be raised to correct the conservative nature of the substitution. The means for making this adjustment are well known to those skilled in the art. See, for example, Pearson (1994) Methods Mol. Biol. 24: 307-331, which is incorporated herein by reference. Examples of amino acid groups with side chains having similar chemical properties include 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; (5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartic acid and glutamic acid; and (7) sulfur-containing side chains: cysteine and methionine. Preferred conservative amino acid substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Alternatively, a conservative substitution is any change that has a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Science 256: 1443 45, which is incorporated herein by reference. A "moderately conservative" substitution is any change that has a non-negative value in the PAM250 log-likelihood matrix.
[0077] Sequence similarity of polypeptides is usually measured using sequence analysis software. Protein analysis software uses similarity measures for various substitutions, deletions and other modifications assigned to, including conservative amino acid substitutions, to match similar sequences. For example, GCG software contains programs such as GAP and BESTFIT, which can be used under default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as between homologous polypeptides from different organism species or between wild-type proteins and their mutant proteins. See, for example, GCG version 6.1. FASTA with default or recommended parameters can also be used to compare polypeptide sequences; the FASTA is a program in the form of GCG version 6.1. FASTA (such as FASTA2 and FASTA3) provides comparison and sequence identity percentage of the best overlap region between the query sequence and the search sequence (Pearson (2000), supra). When comparing the sequence of the present invention with a database containing a large number of sequences from different organisms, another preferred algorithm is a computer program BLAST using default parameters, especially BLASTP or TBLASTN. See, e.g., Altschul et al. (1990) J. Mol. Biol. 215:403-410 and (1997) Nucleic Acids Res. 25:3389-3402, each of which is incorporated herein by reference.
[0078] The phrase "therapeutically effective amount" means an amount that produces the effect it is intended to achieve. The exact amount will depend on the purpose of the treatment and will be determined by one skilled in the art using known techniques (see, e.g., Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding).
[0079] As used herein, the term "subject" refers to an animal, preferably a mammal, more preferably a human being, in need of improvement, prevention and / or treatment of a FXII-related disease or disorder (such as thrombosis or embolism). The term includes human subjects suffering from such a disease or disorder or at risk of suffering from such a disease or disorder.
[0080] As used herein, the term "treat / treating / treatment" refers to reducing or ameliorating the severity of at least one symptom or sign of a FXII-related disease or condition as a result of administering a therapeutic agent (such as an antibody of the invention) to a subject in need thereof. The term includes inhibiting the progression of the disease or inhibiting the worsening of the symptom / sign. The term also includes a positive prognosis for the disease, i.e., after administration of a therapeutic agent (such as an antibody of the invention), the subject may be free of the disease or may suffer from a mitigated disease. The therapeutic agent may be administered to the subject in a therapeutic dose.
[0081] The terms "prevent", "preventing" and "prevention" refer to the inhibition of the manifestation of a FXII-associated disease or disorder, or any symptom or sign of such a disease or disorder, following administration of an antibody of the invention.
[0082] Antigen-binding fragment of an antibody
[0083] Unless otherwise specifically indicated, as used herein, the term "antibody" should be understood to encompass antibody molecules comprising two immunoglobulin heavy chains and two immunoglobulin light chains (i.e., "complete antibody molecules"), as well as antigen-binding fragments thereof. As used herein, the terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, etc. include any naturally occurring, enzymatically obtainable, synthetic or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. As used herein, the term "antigen-binding fragment" or "antibody fragment" of an antibody refers to one or more fragments of an antibody that retains the ability to specifically bind to a FXII protein. Antibody fragments may include Fab fragments, F(ab')2 fragments, Fv fragments, dAb fragments, fragments containing CDRs, or isolated CDRs. In certain embodiments, the term "antigen-binding fragment" refers to a polypeptide fragment of a multispecific antigen-binding molecule. Antigen-binding fragments of an antibody can be derived, for example, from a complete antibody molecule using any suitable standard technique, such as proteolytic digestion or recombinant genetic engineering techniques involving manipulation and expression of DNA encoding antibody variable domains and (optionally) constant domains. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage antibody libraries), or can be synthesized. The DNA can be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and / or constant domains into a suitable configuration, or to introduce codons, generate cysteine residues, modify, add or delete amino acids, etc.
[0084] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) the smallest recognition unit consisting of amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementary determining region (CDR), such as a CDR3 peptide) or a constrained FR3-CDR3-FR4 peptide. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, bifunctional antibodies, trifunctional antibodies, tetrafunctional antibodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs) and shark variable IgNAR domains are also encompassed within the expression "antigen-binding fragment" as used herein.
[0085] The antigen-binding fragment of an antibody will generally contain at least one variable domain. The variable domain may be of any size or amino acid composition and will generally contain at least one CDR adjacent to or in frame with one or more framework sequences. H Domain and V L In the antigen-binding fragment associated with the structural domain, V H and V L The domains may be positioned relative to each other in any suitable arrangement. For example, the variable region may be a dimer and contain V H -V H 、V H -V L or V L -V L Alternatively, the antigen-binding fragment of the antibody may contain a monomer V H or V L Structural domain.
[0086] In certain embodiments, the antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found within the antigen-binding fragment of an antibody of the invention include: (i) V H -C H 1; (ii) V H -C H 2; (iii) V H -C H 3; (iv) V H -C H 1-C H 2; (v) V H -CH 1-C H 2-C H 3; (vi) V H -C H 2-C H 3; (vii) V H -C L ; (viii) V L -C H 1; (ix) V L -C H 2; (x) V L -C H 3; (xi) V L -C H 1-C H 2; (xii) V L -C H 1-C H 2-C H 3; (xiii) V L -C H 2-C H 3; and (xiv) V L -C L . In any configuration of variable and constant domains (including any of the exemplary configurations listed above), the variable and constant domains may be directly connected to each other or may be connected by a complete or partial hinge region or linker region. The hinge region may be composed of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids that create a flexible or semi-flexible linkage between adjacent variable domains and / or constant domains in a single polypeptide molecule. In addition, the antigen-binding fragments of the antibodies of the present invention may comprise non-covalent associations with each other and / or with one or more monomeric V H or V L Homodimers or heterodimers (or other multimers) of any of the variable and constant domain configurations listed above in which the domains are non-covalently associated (e.g., by disulfide bonds).
[0087] As with complete antibody molecules, antigen-binding fragments can be monospecific or multispecific (e.g., bispecific). A multispecific antigen-binding fragment of an antibody will generally contain at least two different variable domains, each of which is capable of specifically binding to a separate antigen or a different epitope on the same antigen. Any multispecific antibody format, including the exemplary bispecific antibody formats disclosed herein, can be adapted for use in the context of antigen-binding fragments of the antibodies of the invention using conventional techniques available in the art.
[0088] Preparation of human antibodies
[0089] Methods for generating human antibodies in transgenic mice are known in the art.Any such known methods may be used in the context of the present invention to make human antibodies that specifically bind to FXII and / or FXIIa.
[0090] An immunogen comprising any of the following may be used to generate antibodies to FXII and / or FXIIa proteins. In certain embodiments, the antibodies of the invention are obtained from mice immunized with full-length native FXII or FXIIa proteins (see, e.g., UniProtKB / Swiss-Prot deposit number P00748.3), or with DNA encoding the protein or fragments thereof. Alternatively, the protein or fragments thereof may be produced using standard biochemical techniques, modified and used as immunogens.
[0091] In some embodiments, the immunogen can be a recombinant FXII protein or a fragment thereof expressed in E. coli or in any other eukaryotic or mammalian cells, such as Chinese Hamster Ovary (CHO) cells.
[0092] use Technology (see, e.g., US 6,596,541, Regeneron Pharmaceuticals, ) or any other known method for generating monoclonal antibodies, a high affinity anti-FXII chimeric antibody having a human variable region and a mouse constant region is initially isolated. The technology involves generating a transgenic mouse having a genome comprising human heavy and light chain variable regions operably linked to endogenous mouse constant region loci, such that the mouse produces antibodies comprising human variable regions and mouse constant regions in response to antigenic stimulation. DNA encoding antibody heavy and light chain variable regions is isolated and operably linked to DNA encoding human heavy and light chain constant regions. The DNA is then expressed in cells capable of expressing fully human antibodies.
[0093] Generally, the antigen of interest is used to challenge Mice, and lymphocytes (such as B cells) are recovered from the mice expressing antibodies. Lymphocytes can be fused with myeloma cell lines to prepare infinite hybridoma cell lines, and such hybridoma cell lines are screened and selected to identify hybridoma cell lines that produce antibodies specific to the antigen of interest. The DNA encoding the heavy chain and light chain variable regions can be separated and connected to the heavy chain and light chain constant regions of the desired isotype. Such antibody proteins can be produced in cells, such as CHO cells. Alternatively, DNA encoding antigen-specific chimeric antibodies or light chain and heavy chain variable domains can be directly isolated from antigen-specific lymphocytes.
[0094] First, high-affinity chimeric antibodies with human variable regions and mouse constant regions are isolated. As in the following experimental section, antibodies are characterized and selected for desirable characteristics, including affinity, selectivity, epitopes, etc. The mouse constant region is replaced with the desired human constant region to generate fully human antibodies of the present invention, such as wild-type or modified IgG1 or IgG4. Although the selected constant region can vary according to a specific use, high-affinity antigen binding and target specificity characteristics are still present in the variable region.
[0095] Bioequivalent
[0096] The anti-FXII antibodies and antibody fragments of the present invention encompass proteins having amino acid sequences that differ from the described antibodies but retain the ability to bind to the FXII protein. Such variant antibodies and antibody fragments comprise one or more amino acid additions, deletions or substitutions when compared to the parent sequence, but exhibit biological activities that are substantially equivalent to the biological activities of the described antibodies. Likewise, the DNA sequences encoding antibodies of the present invention encompass sequences that comprise one or more nucleotide additions, deletions or substitutions when compared to the disclosed sequences, but encode antibodies or antibody fragments that are substantially biologically equivalent to the antibodies or antibody fragments of the present invention.
[0097] If, for example, two antigen-binding proteins or antibodies are pharmaceutical equivalents or pharmaceutical substitutes that do not show significant differences in absorption rate and extent when given at the same molar dose under similar experimental conditions (single dose or multiple doses), then the antigen-binding proteins or antibodies are considered bioequivalent. If some antibodies have the same degree of absorption but different absorption rates, these antibodies are considered equivalents or pharmaceutical substitutes, and because this difference in absorption rate is intentionally generated and reflected in the label, it is not essential for achieving effective body drug concentrations in, for example, long-term use and is considered to have no medical significance for specific drug studies, then they can be considered bioequivalent.
[0098] In one embodiment, two antigen binding proteins are bioequivalent if there are no clinically meaningful differences in safety, purity, and potency.
[0099] In one embodiment, two antigen binding proteins are bioequivalent if patients can switch between the reference product and the biological product one or more times without an expected increased risk of adverse effects, including clinically significant changes in immunogenicity or reduced effectiveness, compared to continued therapy in the absence of switching between the reference product and the biological product.
[0100] In one embodiment, if two antigen binding proteins both act by one or more mechanisms of action that are common for one or more conditions of use, then the two antigen binding proteins are bioequivalent to the extent such mechanisms are known.
[0101] Bioequivalence can be demonstrated by in vivo and / or in vitro methods. Bioequivalence measurements include, for example: (a) in vivo tests in humans or other mammals, where the concentration of the antibody or its metabolites is measured over time in blood, plasma, serum or other biological fluids; (b) in vitro tests that correlate with and are reasonably predictive of human in vivo bioavailability data; (c) in vivo tests in humans or other mammals, where appropriate acute pharmacological effects of the antibody (or its target) are measured over time; and (d) in well-controlled clinical trials to establish the safety, efficacy or bioavailability or bioequivalence of the antibody.
[0102] Bioequivalent variants of the antibodies of the invention can be constructed by, for example, making various substitutions of residues or sequences, or deleting terminal or internal residues or sequences that are not required for biological activity. For example, cysteine residues that are not essential for biological activity can be deleted or replaced with other amino acids to prevent the formation of unnecessary or incorrect intramolecular disulfide bridges during renaturation. In other cases, bioequivalent antibodies can include antibody variants that include amino acid changes that modify the glycosylation characteristics of the antibody, such as mutations that eliminate or remove glycosylation.
[0103] Anti-FXII antibodies containing Fc variants
[0104] According to certain embodiments of the present invention, an anti-FXII antibody comprising an Fc domain is provided, wherein the Fc domain comprises one or more mutations that enhance or attenuate antibody binding to an FcRn receptor, for example, at an acidic pH compared to a neutral pH. For example, the present invention includes an anti-FXII antibody comprising a C of an Fc domain. H 2 or C HA mutation in region 3, wherein the mutation increases the affinity of the Fc domain for FcRn in an acidic environment (e.g., in an endosome at a pH in the range of about 5.5 to about 6.0). When the antibody is administered to an animal, such a mutation may increase the serum half-life of the antibody. Non-limiting examples of such Fc modifications include, e.g., modifications at position 250 (e.g., E or Q); 250 and 428 (e.g., L or F); 252 (e.g., L / Y / F / W or T), 254 (e.g., S or T), and 256 (e.g., S / R / Q / E / D or T); or modifications at positions 428 and / or 433 (e.g., H / L / R / S / P / Q or K) and / or 434 (e.g., A, W, H, F or Y [N434A, N434W, N434H, N434F or N434Y]); or modifications at positions 250 and / or 428; or modifications at positions 307 or 308 (e.g., 308F, V308F) and 434. In one embodiment, the modification comprises 428L (e.g., M428L) and 434S (e.g., N434S) modification; 428L, 259I (e.g., V259I) and 308F (e.g., V308F) modification; 433K (e.g., H433K) and 434 (e.g., 434Y) modification; 252, 254 and 256 (e.g., 252Y, 254T and 256E) modification; 250Q and 428L modification (e.g., T250Q and M428L); and 307 and / or 308 modification (e.g., 308F or 308P). In another embodiment, the modification comprises 265A (e.g., D265A) and / or 297A (e.g., N297A) modification.
[0105] For example, the invention includes an anti-FXII antibody comprising an Fc domain comprising one or more mutation pairs or groups selected from the group consisting of: 250Q and 248L (e.g., T250Q and M248L); 252Y, 254T, and 256E (e.g., M252Y, S254T, and T256E); 428L and 434S (e.g., M428L and N434 S); 257I and 311I (e.g., P257I and Q311I); 257I and 434H (e.g., P257I and N434H); 376V and 434H (e.g., D376V and N434H); 307A, 380A and 434A (e.g., T307A, E380A and N434A); and 433K and 434F (e.g., H433K and N434F). All possible combinations of the aforementioned Fc domain mutations and other mutations within the antibody variable domains disclosed herein are encompassed within the scope of the present invention.
[0106] The present invention also includes a chimeric heavy chain constant (C H ) region of the anti-FXII antibody, wherein the chimeric CH The region contains C sequences derived from more than one immunoglobulin isotype H For example, the antibody of the present invention may comprise a chimeric C H A region comprising a C region derived from a human IgG1, human IgG2 or human IgG4 molecule H 2 domain, and C derived from human IgG1, human IgG2 or human IgG4 molecules H According to certain embodiments, the antibodies of the present invention comprise a chimeric C having a chimeric hinge region. H For example, the chimeric hinge may comprise an "upper hinge" amino acid sequence derived from a human IgG1, human IgG2, or human IgG4 hinge region (amino acid residues from positions 216 to 227 according to EU numbering), and a "lower hinge" sequence derived from a human IgG1, human IgG2, or human IgG4 hinge region (amino acid residues from positions 228 to 236 according to EU numbering). According to certain embodiments, the chimeric hinge region comprises amino acid residues derived from the upper hinge of human IgG1 or human IgG4 and amino acid residues derived from the lower hinge of human IgG2. In certain embodiments, a chimeric hinge region comprising a chimeric C as described herein H Antibodies with modified Fc regions can exhibit modified Fc effector functions without adversely affecting the therapeutic or pharmacokinetic properties of the antibodies. (See, e.g., U.S. Patent Application Publication No. 2014 / 0243504, the disclosure of which is incorporated herein by reference in its entirety).
[0107] Biocharacterization of antibodies
[0108] In general, the antibodies of the invention function by binding to the FXII protein and preventing its cleavage into FXIIa and FXIIb. In certain embodiments, the antibodies bind to the activated form of factor XII (FXIIa) ("dual FXII / FXIIa conjugate"). For example, the invention includes antibodies and antigen-binding fragments of antibodies that bind to the activated form of factor XII (FXIIa) with a K of less than 20 nM. D Binding to FXII protein (e.g., at 25°C or 37°C), as measured, for example, by surface plasmon resonance using an assay format as defined in Example 3 herein. In certain embodiments, the antibody or antigen-binding fragment thereof has a K of less than about 20 nM, less than about 17 nM, less than about 10 nM, less than about 5 nM, or less than about 1 nM. D Binding to FXII as measured, for example, by surface plasmon resonance using an assay format as defined in Example 3 herein, or a substantially similar assay.
[0109] The present invention also includes antibodies and antigen-binding fragments thereof that bind to human FXII protein with a dissociation half-life (t1 / 2) of greater than about 1 minute, as measured, for example, by surface plasmon resonance using an assay format as defined herein in Example 3 or a substantially similar assay at 25° C. or 37° C. In certain embodiments, the antibodies or antigen-binding fragments of the invention bind to FXII protein with a t1 / 2 of greater than about 5 minutes, greater than about 10 minutes, greater than about 20 minutes, greater than about 30 minutes, greater than about 40 minutes, greater than about 50 minutes, greater than about 60 minutes, or greater than about 70 minutes, as measured, for example, by surface plasmon resonance using an assay format as defined herein in Example 3 or a substantially similar assay at 25° C. or 37° C.
[0110] The present invention includes antibodies and antigen-binding fragments of antibodies that have a K of less than 9 nM. D Binding to FXIIa protein (e.g., at 25°C or 37°C), as measured, for example, by surface plasmon resonance using an assay format as defined in Example 3 herein. In certain embodiments, the antibody or antigen-binding fragment thereof has a K of less than about 9 nM, less than about 5 nM, less than about 2 nM, less than about 1 nM, or less than about 500 pM. D Binding to FXIIa as measured, for example, by surface plasmon resonance using an assay format as defined in Example 3 herein or a substantially similar assay.
[0111] The present invention also includes antibodies and antigen-binding fragments thereof that bind to human FXIIa protein with a dissociation half-life (t1 / 2) of greater than about 1 minute, as measured, for example, by surface plasmon resonance using an assay format as defined in Example 3 herein, or a substantially similar assay, at 25° C. or 37° C. In certain embodiments, the antibodies or antigen-binding fragments of the invention bind to FXIIa protein with a t1 / 2 of greater than about 5 minutes, greater than about 10 minutes, greater than about 20 minutes, greater than about 30 minutes, greater than about 40 minutes, greater than about 50 minutes, greater than about 60 minutes, or greater than about 70 minutes, as measured, for example, by surface plasmon resonance at 25° C. or 37° C. using an assay format as defined in Example 3 herein, or a substantially similar assay.
[0112] The present invention also includes antibodies and antigen-binding fragments thereof that inhibit thrombin generation by the intrinsic pathway at a concentration of less than 250 nM, less than 200 nM, or less than 150 nM, as measured, for example, using an assay format as described in Example 5 herein, or a substantially similar assay. In certain embodiments, the present invention includes antibodies and antigen-binding fragments thereof that inhibit thrombin generation by the intrinsic pathway without blocking thrombin generation by the extrinsic pathway, as measured, for example, using an assay format as described in Example 5 herein, or a substantially similar assay.
[0113] In one embodiment, the present invention provides an isolated recombinant antibody or antigen-binding fragment thereof that specifically binds to a FXII protein, wherein the antibody or fragment thereof exhibits one or more of the following characteristics: (a) being a fully human monoclonal antibody; (b) binding to activated factor XII (FXIIa); (c) binding to FXIIa with a dissociation constant (K) of less than 3.5 nM at 25° C. as measured in a surface plasmon resonance assay; D ) binds to FXII with a K of less than 17 nM at 37°C as measured in a surface plasmon resonance assay; (d) binds to FXII with a K of less than 17 nM at 37°C D (e) binds to FXII with a K of less than 5 nM, preferably less than 2.5 nM at 25°C as measured in a surface plasmon resonance assay; D (f) binds to FXIIa with a K of less than 6.5 nM, preferably less than 2.5 nM at 37°C as measured in a surface plasmon resonance assay; D Binds to FXIIa; (g) blocks thrombin generation by the intrinsic pathway at a concentration of less than 250 nM as measured by a functional plasma assay; and (h) blocks thrombin generation by the intrinsic pathway without blocking thrombin generation by the extrinsic pathway as measured by a functional plasma assay.
[0114] The antibodies of the invention may have one or more of the aforementioned biological characteristics, or any combination thereof. Other biological characteristics of the antibodies of the invention will be apparent to those of ordinary skill in the art upon review of the present disclosure, including the working examples herein.
[0115] Epitope mapping and related technologies
[0116] The present invention includes anti-FXII / FXIIa antibodies that interact with one or more amino acids found in one or more regions of FXII / FXIIa protein molecules, including heavy and light chains. The epitope to which the antibody binds may consist of a single continuous sequence of 3 or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) amino acids located within any of the aforementioned domains of the FXII protein molecule (e.g., a linear epitope in a domain). Alternatively, the epitope may consist of a plurality of non-continuous amino acids (or amino acid sequences) located within any or both of the aforementioned domains of the protein molecule (e.g., a conformational epitope).
[0117] Various techniques known to those of ordinary skill in the art can be used to determine whether an antibody interacts with "one or more amino acids" within a polypeptide or protein. Exemplary techniques include, for example, conventional cross-blocking analysis, such as the analysis described in Harlow and Lane's Antibodies (Cold Spring Harbor Press, Cold Spring Harbor, NY). Other methods include alanine scanning mutation analysis, peptide blot analysis (Reineke (2004) Methods in Molecular Biology 248: 443-63), peptide cleavage analysis crystallographic studies and NMR analysis. In addition, methods such as epitope excision, epitope extraction and chemical modification of antigens can be used (Tomer (2000), Protein Science 9: 487-496). Another method that can be used to identify amino acids in polypeptides that interact with antibodies is hydrogen / deuterium exchange detected by mass spectrometry. In general, hydrogen / deuterium exchange methods include labeling the protein of interest with deuterium, followed by binding of the antibody to the deuterium-labeled protein. Next, the protein / antibody complex is transferred to water and the exchangeable protons in the amino acid protected by the antibody complex undergo deuterium-hydrogen reverse exchange, and its reverse exchange rate is slower than the exchangeable protons in the amino acid that is not part of the interface. Therefore, the amino acid that forms a part of the protein / antibody interface may retain deuterium, and therefore shows a relatively high mass compared to the amino acid that is not included in the interface. After the antibody dissociates, the target protein is subjected to protease cleavage and mass spectrometry, thereby revealing deuterium-labeled residues that correspond to specific amino acids that interact with the antibody. See, for example, Ehring (1999) "Analytical Biochemistry (Analytical Biochemistry)" 267: 252-259; Engen and Smith (2001) "Analytical Chemistry (Anal. Chem.)" 73: 256A-265A.
[0118] The term "epitope" refers to a site on an antigen to which B cells and / or T cells react. B cell epitopes can be formed by continuous amino acids or non-continuous amino acids connected by tertiary folding of proteins. Epitopes formed by continuous amino acids are usually retained when exposed to denaturing solvents, while epitopes formed by tertiary folding are usually lost when treated with denaturing solvents. Epitopes usually include at least 3 and more usually at least 5 or 8-10 amino acids in a unique spatial conformation.
[0119] Modification-Assisted Profiling (MAP), also known as Antigen Structure-Based Antibody Profiling (ASAP), is a method for classifying a large number of monoclonal antibodies (mAbs) against the same antigen based on the similarity of each antibody's binding profile to a chemically or enzymatically modified antigen surface (see US 2004 / 0101920, specifically incorporated herein by reference in its entirety). Each class can reflect a unique epitope that is significantly different from or partially overlaps with an epitope represented by another class. This technique allows rapid filtering of genetically identical antibodies, thereby allowing characterization to be focused on genetically distinct antibodies. When applied to hybridoma screening, MAP can facilitate the identification of rare hybridoma clones that produce mAbs with desired characteristics. MAP can be used to sort the antibodies of the present invention into groups of antibodies that bind to different epitopes.
[0120] In certain embodiments, the present invention includes anti-FXII antibodies and antigen-binding fragments thereof that interact with one or more epitopes found within the heavy and / or light chains of FXIIa. The epitope may consist of one or more consecutive sequences of 3 or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) amino acids located within the heavy and / or light chains of FXIIa. Alternatively, the epitope may consist of multiple non-contiguous amino acids (or amino acid sequences) located within FXIIa.
[0121] The present invention includes anti-FXII antibodies that bind to the same epitope or a portion of an epitope as any of the specific exemplary antibodies listed in Table 1. Likewise, the present invention also includes anti-FXII antibodies that compete with any of the specific exemplary antibodies listed in Table 1 for binding to a FXII protein or a fragment thereof. For example, the present invention includes anti-FXII antibodies that cross-compete with one or more of the antibodies listed in Table 1 for binding to a FXII protein.
[0122] Whether an antibody binds to the same epitope as a reference anti-FXII antibody, or competes for binding with a reference anti-FXII antibody, can be easily determined by using conventional methods known in the art. For example, to determine whether a test antibody binds to the same epitope as a reference anti-FXII antibody of the present invention, the reference antibody is allowed to bind to a FXII protein or peptide under saturation conditions. Next, the ability of the test antibody to bind to a FXII protein molecule is assessed. If the test antibody is able to bind to FXII after saturation binding of FXII to the reference anti-FXII antibody, it can be inferred that the test antibody binds to an epitope different from that of the reference anti-FXII antibody. On the other hand, if the test antibody is unable to bind to the FXII protein after saturation binding of FXII to the reference anti-FXII antibody, the test antibody may bind to the same epitope as the epitope bound by the reference anti-FXII antibody of the present invention.
[0123] To determine whether an antibody competes for binding with a reference anti-FXII antibody, the binding method described above is performed in two directions: in the first direction, the reference antibody is allowed to bind to the FXII protein under saturating conditions, followed by evaluation of the binding of the test antibody to the FXII molecule. In the second direction, the test antibody is allowed to bind to the FXII molecule under saturating conditions, followed by evaluation of the binding of the reference antibody to the FXII molecule. If in both directions, only the first (saturated) antibody is able to bind to the FXII molecule, then it is inferred that the test antibody and the reference antibody compete for binding to FXII. As will be appreciated by one of ordinary skill in the art, an antibody that competes for binding with a reference antibody may not necessarily bind to the same epitope as the reference antibody, but may sterically block the binding of the reference antibody by binding to an overlapping or adjacent epitope.
[0124] If two antibodies each competitively inhibit (block) the binding of another antibody to an antigen, the two antibodies bind to the same or overlapping epitopes. That is, as measured in a competitive binding assay, 1, 5, 10, 20 or 100 times excess of one antibody inhibits the binding of another antibody by at least 50%, but preferably 75%, 90% or even 99% (see, e.g., Junghans et al., Cancer Res. 1990 50: 1495-1502). Alternatively, if substantially all amino acid mutations that reduce or eliminate the binding of one antibody in an antigen reduce or eliminate the binding of another antibody, the two antibodies have the same epitope. If some amino acid mutations that reduce or eliminate the binding of one antibody reduce or eliminate the binding of another antibody, the two antibodies have overlapping epitopes.
[0125] Additional routine experiments (e.g., peptide mutations and binding analysis) can then be performed to confirm whether the observed lack of binding of the test antibody is actually due to binding to the same epitope as the reference antibody or whether steric blocking (or another phenomenon) is causing the observed lack of binding. Such experiments can be performed using ELISA, RIA, surface plasmon resonance, flow cytometry, or any other quantitative or qualitative antibody binding assay available in the art.
[0126] Immunoconjugates
[0127] The present invention encompasses human anti-FXII monoclonal antibodies conjugated to a therapeutic moiety ("immunoconjugate") to treat FXII-related diseases or conditions (e.g., thrombosis). As used herein, the term "immunoconjugate" refers to an antibody chemically or biologically linked to a radiopharmaceutical, cytokine, interferon, target or reporter moiety, enzyme, peptide or protein, or therapeutic agent. The antibody can be linked to a radiopharmaceutical, cytokine, interferon, target or reporter moiety, enzyme, peptide or therapeutic agent at any position along the molecule, as long as the antibody is able to bind its target. Examples of immunoconjugates include antibody drug conjugates and antibody toxin fusion proteins. In one embodiment, the agent can be a second different antibody to the FXII protein. The type of therapeutic moiety can be conjugated to the anti-FXII antibody and will take into account the condition to be treated and the desired therapeutic effect to be achieved. Examples of suitable agents for forming immunoconjugates are known in the art; see, for example, WO 05 / 103081.
[0128] Multispecific Antibodies
[0129] The antibodies of the present invention may be monospecific, bispecific or multispecific. Multispecific antibodies may be specific for different epitopes of a target polypeptide, or may contain antigen binding domains that are specific for more than one target polypeptide. See, for example, Tutt et al., 1991, J. Immunol. 147:60-69; Kufer et al., 2004, Trends Biotechnol. 22:238-244.
[0130] Any of the multispecific antigen-binding molecules of the invention, or variants thereof, can be constructed using standard molecular biology techniques (eg, recombinant DNA and protein expression techniques), as would be known to one of ordinary skill in the art.
[0131] In some embodiments, FXII-specific antibodies are generated in a bispecific format ("bispecific") in which variable regions that bind to different domains of the FXII protein are linked together to bring about dual domain specificity within a single binding molecule. Appropriately designed bispecifics can enhance the overall inhibitory efficacy of the FXII protein by increasing specificity and binding affinity. Variable regions that are specific for individual domains (e.g., segments of the N-terminal domain), or that can bind to different regions within a domain, are paired on a structural scaffold that allows each region to bind to a separate epitope simultaneously, or to different regions within a domain. In one example of a bispecific, a heavy chain variable region (V) from a binder that is specific for one domain and a variable region (V) from a binder that is specific for one domain. H ) with a light chain variable region (V L) to identify the original V H Pairing without destroying V H The original specific non-homologous V L In this way, a single V L Segment (e.g., V L 1) Can be used with two different V H Domains (e.g., V H 1 and V H 2) Combine to generate a H 1-V L 1 and V H 2-V L 1) Composition of bispecific. Using a single V L The segments reduce the complexity of the system and thereby simplify and improve the efficiency of the cloning, expression and purification processes for generating bispecifics (see, e.g., USSN 13 / 022759 and US 2010 / 0331527).
[0132] Alternatively, antibodies that bind more than one domain and a second target (such as, but not limited to, for example, a second different anti-FXII antibody) can be prepared in a bispecific format using the techniques described herein or other techniques known to those of ordinary skill in the art. Antibody variable regions that bind to different regions can be linked together with variable regions that bind to, for example, the relevant sites on the extracellular domain of FXII to bring about dual antigen specificity in a single binding molecule. This bispecific property, appropriately designed, provides dual functionality. Variable regions that are specific to the extracellular domain are combined with variable regions that are specific outside the extracellular domain and paired on a structural scaffold so that each variable region binds to a separate antigen.
[0133] An exemplary bispecific antibody format that can be used in the context of the present invention involves the use of a first immunoglobulin (Ig) C H 3 domain and the second Ig C H 3 domains, wherein the first and second Ig C H The three domains differ from each other by at least one amino acid, and wherein the at least one amino acid difference reduces binding of the bispecific antibody to protein A compared to a bispecific antibody lacking the amino acid difference. H The 3 domains bind protein A and the second Ig C H The 3 domain contains a mutation that reduces or eliminates protein A binding, such as the H95R modification (according to IMGT exon numbering: H435R according to EU numbering). H 3 may further comprise a Y96F modification (according to IMGT; Y436F according to Eu). HOther modifications within 3 include: in the case of IgG1 antibodies, D16E, L18M, N44S, K52N, V57M and V82I (according to IMGT; D356E, L358M, N384S, K392N, V397M and V422I according to EU); in the case of IgG2 antibodies, N44S, K52N and V82I (IMGT; N384S, K392N and V422I according to EU); and in the case of IgG4 antibodies, Q15R, N44S, K52N, V57M, R69K, E79Q and V82I (according to IMGT; Q355R, N384S, K392N, V397M, R409K, E419Q and V422I according to EU). Variations of the bispecific antibody formats described above are encompassed within the scope of the present invention.
[0134] Other exemplary bispecific formats that can be used in the present invention include, but are not limited to, for example, ScFv-based or bifunctional antibody bispecific formats, IgG-scFv fusions, dual variable domains (DVD)-Ig, quadromas, knobs-into-holes, common light chains (e.g., common light chains with knobs in holes, etc.), CrossMab, CrossFab, (SEED) body, leucine zipper, Duobody, IgG1 / IgG2, dual-acting Fab (DAF)-IgG and Mab 2 Bispecific formats (for a review of the aforementioned formats, see, e.g., Klein et al., 2012, mAbs 4:6, 1-11, and references cited therein). Bispecific antibodies can also be constructed using peptide / nucleic acid conjugation, for example, where non-natural amino acids with orthogonal chemical reactivity are used to generate site-specific antibody-oligonucleotide conjugates, which are then self-assembled into multimeric complexes with defined composition, valency, and geometry. (See, e.g., Kazane et al., J. Am. Chem. Soc. [Electronic version: Dec. 4, 2012]).
[0135] Therapeutic administration and formulations
[0136] The present invention provides therapeutic compositions comprising anti-FXII antibodies or antigen-binding fragments thereof of the present invention. The therapeutic compositions according to the present invention will be administered with suitable carriers, excipients, and other agents incorporated into the formulation to provide improved transport, delivery, tolerance, etc. Many suitable formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, gels, waxes, oils, lipids, vesicles containing lipids (cationic or anionic lipids) (such as LIPOFECTIN TM ), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsion carbowax (polyethylene glycols of various molecular weights), semisolid gels, and semisolid mixtures containing carbowax. See also Powell et al., "Compendium of excipients for parenteral formulations", PDA (1998) J Pharm Sci Technol 52:238-311.
[0137] The dosage of the antibody may vary depending on the age and physique of the subject, the target disease, the condition, the route of administration, etc. When the antibody of the present invention is used to treat a disease or condition in an adult patient or to prevent such a disease, it is advantageous to generally administer the antibody of the present invention in a single dose of about 0.1 to about 100 mg / kg body weight. Depending on the severity of the condition, the frequency and duration of treatment may be adjusted. In certain embodiments, the antibody of the present invention or its antigen-binding fragment may be administered at an initial dose of at least about 0.1 mg to about 800 mg, about 1 to about 600 mg, about 5 to about 500 mg, or about 10 to about 400 mg. In certain embodiments, a second or more subsequent dose of the antibody or its antigen-binding fragment may be administered after the initial dose, the amount of which may be approximately equal to or less than the amount of the initial dose, wherein the subsequent doses are spaced at least 1 day to 3 days; at least one week, at least 2 weeks; at least 3 weeks; at least 4 weeks; at least 5 weeks; at least 6 weeks; at least 7 weeks; at least 8 weeks; at least 9 weeks; at least 10 weeks; at least 12 weeks; or at least 14 weeks.
[0138] Various delivery systems are known and can be used to administer the pharmaceutical compositions of the invention, for example, encapsulated in the form of liposomes, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses, receptor-mediated endocytosis (see, for example, Wu et al. (1987) J. Biol. Chem. 262: 4429-4432). Methods of introduction include, but are not limited to, intradermal, transdermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The composition can be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered together with other bioactive agents. It can be administered systemically or topically. The pharmaceutical composition can also be delivered in the form of vesicles, particularly liposomes (see, for example, Langer (1990) Science 249: 1527-1533).
[0139] The use of nanoparticles to deliver antibodies of the present invention is also contemplated herein. Antibody-conjugated nanoparticles can be used for therapeutic and diagnostic applications. Antibody-conjugated nanoparticles and methods for preparation and use are described in detail by Arruebo, M. et al., 2009 ("Antibody-conjugated nanoparticles for biomedical applications" in "J. Nanomat.", 2009 volume, article number 439389, 24 pages, doi: 10.1155 / 2009 / 439389), which is incorporated herein by reference. Nanoparticles can be developed and conjugated to targeted cells with antibodies contained in pharmaceutical compositions. Nanoparticles for drug delivery have also been described in, for example, US 8257740 or US 8246995, each of which is incorporated herein in its entirety.
[0140] In some cases, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump can be used. In another embodiment, a polymeric material can be used. In yet another embodiment, the controlled release system can be placed near the target of the composition, thereby requiring only a portion of the systemic dose.
[0141] The injectable preparations may include dosage forms for intravenous, subcutaneous, intracranial, intraperitoneal and intramuscular injections, drip infusions, etc. These injectable preparations can be prepared by publicly known methods.
[0142] The pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously with a standard needle and syringe. In addition, for subcutaneous delivery, a pen delivery device is easily used to deliver the pharmaceutical composition of the present invention. Such a pen delivery device can be reusable or disposable. Reusable pen delivery devices generally utilize a replaceable cartridge containing the pharmaceutical composition. Once the entire pharmaceutical composition in the cartridge has been administered and the cartridge is empty, the empty cartridge can be easily discarded and replaced with a new cartridge containing the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. In contrast, a disposable pen delivery device is preloaded with a pharmaceutical composition held in a reservoir within the device. Once the pharmaceutical composition in the reservoir is emptied, the entire device is discarded.
[0143] Advantageously, the pharmaceutical composition for oral or parenteral use described above is prepared in a dosage form suitable for a unit dose that meets the dosage of the active ingredient. Such dosage forms in unit doses include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc. The amount of antibody contained is generally about 5 to about 500 mg per unit dose dosage form; particularly in the form of injection, it is preferred that the content of the antibody is about 5 to about 300 mg, and about 10 to about 300 mg for other dosage forms.
[0144] Therapeutic uses of antibodies
[0145] The antibodies of the present invention are suitable for treating and / or preventing diseases or disorders or conditions associated with coagulation (including thrombosis and embolism) or edema (e.g., hereditary angioedema), and / or for improving at least one symptom associated with such diseases, disorders or conditions. In certain embodiments, the antibodies of the present invention or their antigen-binding fragments can be administered to patients suffering from diseases or disorders or conditions associated with coagulation or edema at therapeutic doses. In certain embodiments, the antibodies of the present invention or their antigen-binding fragments are administered to subjects in need to prevent thrombosis without increasing the risk of bleeding.
[0146] In certain embodiments, the antibodies of the invention are useful for treating or preventing at least one symptom or sign of a FXII-related disease or disorder selected from the group consisting of venous thrombosis, arterial thrombosis, device thrombosis, thromboembolism, hereditary angioedema, stroke, thrombophilia, myocardial ischemia, atherosclerotic plaque rupture, mechanical valve prosthesis use-related disorders, blood-contacting medical device use-related disorders, blood-contacting extracorporeal circulation use-related disorders, venous thromboembolism, pulmonary embolism, deep vein thrombosis, portal vein thrombosis, Budd-Chiari syndrome, Paget-Schroetter disease, renal vein thrombosis, cerebral venous sinus thrombosis, jugular vein thrombosis, cavernous sinus thrombosis, hepatic artery thrombosis, limb ischemia, and myocardial infarction.
[0147] It is also contemplated herein to use one or more antibodies of the invention prophylactically in subjects at risk of thrombosis, such as subjects using extracorporeal membrane oxygenation (heart-lung machine). The antibodies of the invention can be used to prevent thrombotic occlusions caused by oxygenators and tubing in extracorporeal circuits.
[0148] In another embodiment of the invention, the antibodies of the invention are used to prepare pharmaceutical compositions or agents for treating patients suffering from diseases, disorders or conditions disclosed herein. In another embodiment of the invention, the antibodies of the invention are used as adjuvant therapy together with any other agent or any other therapy known to those skilled in the art to be suitable for treating or ameliorating diseases, disorders or conditions disclosed herein.
[0149] Combination therapy
[0150] Combination therapy can include an antibody of the invention and any additional therapeutic agent that can be advantageously combined with an antibody of the invention or with a biologically active fragment of an antibody of the invention. The antibody of the invention can be combined synergistically with one or more drugs or therapies for treating a disease or condition associated with thrombosis, specifically, to prevent thrombosis or treat a subject at risk of thrombosis due to an underlying disease, condition, or condition (described elsewhere herein). In some embodiments, the antibody of the invention can be combined with a second therapeutic agent to improve one or more symptoms of the disease or condition.
[0151] Depending on the disease, disorder or condition, the antibodies of the invention may be used in combination with one or more additional therapeutic agents, including but not limited to anticoagulants (e.g., warfarin, heparin, phenindione, fondaparinux, edaparinux), thrombin inhibitors (e.g., argatroban, lepirudin, bivalirudin or dabigatran), thrombolytics, antiplatelet drugs (e.g., aspirin), antihypertensives (e.g., angiotensin-converting enzyme inhibitors, beta blockers, calcium channel blockers), immunosuppressants (such as vincristine, cyclosporine A or methotrexate), fibrinolytics, cholesterol-lowering agents (e.g., statins or PCSK9 inhibitors (such as alirocumab)), anti-inflammatory drugs (such as corticosteroids, or nonsteroidal anti-inflammatory drugs), a second anti-FXII antibody, mechanical thrombectomy, catheter-directed thrombolysis, and surgery.
[0152] As used herein, the term "in combination with" means that the additional therapeutically active component can be administered before, simultaneously with, or after the administration of the anti-FXII antibody of the invention. The term "in combination with" also includes sequential or concomitant administration of the anti-FXII antibody and the second therapeutic agent.
[0153] The additional therapeutically active component may be administered to the subject prior to administration of the anti-FXII antibodies of the invention. For example, if the first component is administered 1 week prior to administration of the second component, 72 hours prior to administration, 60 hours prior to administration, 48 hours prior to administration, 36 hours prior to administration, 24 hours prior to administration, 12 hours prior to administration, 6 hours prior to administration, 5 hours prior to administration, 4 hours prior to administration, 3 hours prior to administration, 2 hours prior to administration, 1 hour prior to administration, 30 minutes prior to administration, or less than 30 minutes prior to administration, the first component may be considered to be administered "before" the second component. In other embodiments, the additional therapeutically active component may be administered to the subject after administration of the anti-FXII antibodies of the invention. For example, if the first component is administered 30 minutes after administration of the second component, 1 hour after administration, 2 hours after administration, 3 hours after administration, 4 hours after administration, 5 hours after administration, 6 hours after administration, 12 hours after administration, 24 hours after administration, 36 hours after administration, 48 hours after administration, 60 hours after administration, 72 hours after administration, or more, the first component may be considered to be administered "after" the second component. In yet other embodiments, the additional therapeutically active component may be administered to the subject at the same time as the anti-FXII antibodies of the invention. For purposes of the present invention, "simultaneous" administration includes, for example, administering an anti-FXII antibody and an additional therapeutically active component to a subject in a single dosage form or in separate dosage forms that are administered to the subject within about 30 minutes or less of each other. If administered in separate dosage forms, each dosage form may be administered via the same route (e.g., the anti-FXII antibody and the additional therapeutically active component may be administered intravenously, etc.); alternatively, each dosage form may be administered via different routes (e.g., the anti-FXII antibody may be administered intravenously and the additional therapeutically active component may be administered orally). In any case, for purposes of the present disclosure, administering the components in a single dosage form, in separate dosage forms, or in separate dosage forms by different routes is considered "simultaneous administration." For purposes of the present disclosure, administering an anti-FXII antibody "before," "concurrently," or "after" the administration of an additional therapeutically active component (as those terms are defined herein above) is considered administering the anti-FXII antibody "in combination with" the additional therapeutically active component.
[0154] The invention includes pharmaceutical compositions in which the anti-FXII antibodies of the invention are co-formulated with one or more of the additional therapeutically active ingredients as described elsewhere herein.
[0155] Diagnostic Uses of Antibodies
[0156] The antibodies of the invention can be used, for example, to detect and / or measure FXII in a sample for diagnostic purposes. Some embodiments encompass the use of one or more antibodies of the invention in an assay to detect a FXII-related disease or condition. An exemplary diagnostic assay for FXII can comprise, for example, contacting a sample obtained from a patient with an anti-FXII antibody of the invention, wherein the anti-FXII antibody is labeled with a detectable label or reporter molecule or used as a capture ligand to selectively separate FXII from a patient sample. Alternatively, an unlabeled anti-FXII antibody can be used in diagnostic applications in combination with a second antibody that is itself detectably labeled. The detectable label or reporter molecule can be a radioactive isotope, such as 3 H. 14 C. 32 P. 35 S or 125 I; fluorescent or chemiluminescent moieties, such as fluorescein isothiocyanate or rhodamine; or enzymes, such as alkaline phosphatase, β-galactosidase, horseradish peroxidase, or luciferase. Specific exemplary assays that can be used to detect or measure FXII in a sample include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS).
[0157] Samples that can be used for FXII diagnostic analysis according to the present invention include any tissue or fluid sample that can be obtained from a patient under normal or pathological conditions, which contains a detectable amount of FXII protein or its fragment. In general, the content of FXII protein in a specific sample obtained from a healthy patient (e.g., a patient not suffering from a disease associated with FXII) will be measured to initially determine the baseline or standard content of FXII. This baseline content of FXII can then be compared with the content of FXII measured in a sample obtained from an individual suspected of having a FXII-related condition or symptoms associated with such a condition.
[0158] Antibodies specific for FXII protein may not contain additional labels or moieties, or the antibodies may contain N-terminal or C-terminal labels or moieties. In one embodiment, the label or moiety is biotin. In a binding assay, the position of the label (if any) can determine the orientation of the peptide relative to the surface to which the peptide is bound. For example, if the surface is coated with avidin, a peptide containing N-terminal biotin will be oriented so that the C-terminal portion of the peptide will be distal to the surface.
[0159] Examples
[0160] The following examples are set forth to provide a person of ordinary skill in the art with a complete disclosure and description of how to make and use the methods and compositions of the present invention, and the examples are not intended to limit the scope of what the inventors consider to be their invention. Efforts have been made to ensure accuracy with respect to the numbers used (e.g., amounts, temperatures, etc.), but some experimental errors and deviations should be taken into account. Unless otherwise indicated, parts are parts by weight, molecular weights are average molecular weights, temperatures are in degrees Celsius, room temperature is about 25°C, and pressures are at or near atmospheric pressure.
[0161] Example 1: Generation of human antibodies against Factor XII / activated Factor XII (FXII / FXIIa) protein
[0162] In a DNA sequence comprising the variable regions of human immunoglobulin heavy and kappa light chains Human antibodies to FXII / FXIIa proteins were generated in mice. Mice were immunized with plasma purified human FXII and FXIIa proteins (Enzyme Research Laboratories).
[0163] As described in U.S. Pat. No. 7,582,298, which is specifically incorporated herein by reference in its entirety, anti-FXII antibodies were isolated directly from antigen-positive mouse B cells without fusion to myeloma cells. Using this approach, several fully human anti-FXII antibodies (i.e., antibodies having human variable domains and human constant domains) were obtained; exemplary antibodies generated in this manner are designated mAb26036, mAb26048, mAb26049, and mAb26076.
[0164] The biological properties of exemplary antibodies generated according to the methods of this example are described in detail in the examples set forth below.
[0165] Example 2: Amino Acid and Nucleotide Sequences of Heavy and Light Chain Variable Regions
[0166] Table 1 lists the amino acid sequence identifiers of the heavy chain and light chain variable regions and CDRs of selected anti-FXII antibodies of the present invention.
[0167] Table 1: Amino Acid Sequence Identifiers
[0168]
[0169] The corresponding nucleic acid sequence identifiers are listed in Table 2.
[0170] Table 2: Nucleotide sequence identifiers
[0171]
[0172] The antibodies mentioned herein generally have fully human variable regions, but may have human or mouse constant regions. As will be appreciated by those of ordinary skill in the art, antibodies with specific Fc isotypes can be converted into antibodies with different Fc isotypes (e.g., antibodies with mouse IgG1 Fc can be converted into antibodies with human IgG4, etc.), but in any case, variable domains (including CDRs) (which are indicated by the digital identifiers shown in Table 2) will remain the same, and regardless of the nature of the Fc domains, the binding properties for antigens are expected to be the same or substantially similar. In certain embodiments, the selected antibodies with mouse IgG1 Fc are converted into antibodies with human IgG4 Fc. In one embodiment, the IgG4 Fc domains include 2 or more amino acid changes as disclosed in US20100331527. In one embodiment, human IgG4 Fc includes a mutation (S108P) from serine to proline in the hinge region to promote dimer stabilization.
[0173] The control constructs used in the following examples
[0174] For comparison purposes, the following control construct (anti-FXII antibody) was included in the experiments disclosed herein: Comparison 1 ”, i.e., a V with antibody “3F7” against human FXII / FXIIa according to U.S. Patent No. 9,518,127 H / V L sequence (CSL Behring GmbH); and Comparison 2 ”, i.e., a V with antibody “15H8” against human FXII according to U.S. Patent No. 9,574,013 H / V L Sequence of human monoclonal antibody (Vanderbilt Univ. / Aronora).
[0175] Example 3: Antibodies binding to FXII as determined by surface plasmon resonance
[0176] The equilibrium dissociation constants (K) of different FXII reagents binding to purified anti-FXII monoclonal antibodies were determined using a real-time surface plasmon resonance-based Biacore 4000 biosensor. D). All binding studies were performed at 25°C and 37°C in 10 mM HEPES, 300 mM NaCl and 0.05% v / v surfactant Tween-20, pH 7.4 (HBS-P) running buffer. The Biacore CM5 sensor chip surface was first derivatized by amine coupling with a mouse anti-human Fc specific monoclonal antibody (GE Healthcare catalog number BR100839) to capture anti-FXII monoclonal antibodies. Binding studies were performed on human FXII and FXIIa (Enzyme Research Laboratories, catalog numbers 1212 and 1212a, respectively). Different concentrations of hFXII and hFXIIa (50 nM-3.125 nM; 2-fold serial dilutions) were first prepared in HBS-P running buffer and injected on the anti-human Fc captured anti-FXII monoclonal antibody surface at a flow rate of 30 μL / min for 3 minutes, while the dissociation of the monoclonal antibody bound to the FXII reagent was monitored in HBS-P running buffer for 5 minutes. The association rates (k) were determined by fitting the real-time binding sensorgrams to a 1:1 binding model with mass transport limitation using Scrubber 2.0c curve fitting software. a ) and dissociation rate (k d The binding and dissociation equilibrium constant (K) was calculated based on the kinetic rate. D ) and dissociation half-life (t1 / 2), such as:
[0177] and
[0178] The binding kinetic parameters of hFXII or hFXIIa binding to different anti-FXII monoclonal antibodies of the present invention at 25°C and 37°C are shown in Tables 3 to 6.
[0179] Table 3: Binding kinetic parameters of hFXII binding to selected antibodies at 25°C
[0180]
[0181] Table 4: Binding kinetic parameters of hFXII binding to selected antibodies at 37°C
[0182]
[0183]
[0184] Table 5: Binding kinetic parameters of hFXIIa binding to selected antibodies at 25°C
[0185]
[0186] Table 6: Binding kinetic parameters of hFXIIa binding to selected antibodies at 37°C
[0187]
[0188] At 25°C, the KD values of the antibodies binding to hFXII ranged from 0.88 nM to 3.12 nM, as shown in Table 3. At 37°C, the KD values of the antibodies binding to hFXII ranged from 2.53 nM to 16.8 nM, as shown in Table 4.
[0189] At 25°C, the KD values of the antibodies binding to hFXIIa ranged from 0.61 nM to 5.07 nM, as shown in Table 5. At 37°C, the KD values of the antibodies binding to hFXIIa ranged from 1.79 nM to 8.25 nM, as shown in Table 6.
[0190] Example 4: Octet cross-competition analysis
[0191] Binding competition between anti-FXII monoclonal antibodies was determined on OctetHTX biosensors (Pall ForteBio Corp.) using real-time, label-free biolayer interferometry analysis. The entire experiment was carried out at 25°C in 0.01M HEPES (pH 7.4), 0.15M NaCl, 0.05% v / v surfactant Tween-20, 0.1mg / mL BSA (Octet HBS-P buffer), with the plate oscillating at a speed of 1000rpm. In order to evaluate whether the two antibodies can compete with each other for binding to their corresponding epitopes (ERL) on human FXII, first, about 0.42-0.53nm of anti-human FXII monoclonal antibodies were captured to the tip by immersing the Octet biosensor tip (Pall ForteBio Corp., No. 18-5060) coated with anti-hFc antibodies into the well containing 50μg / mL anti-human FXII monoclonal antibodies (hereinafter referred to as mAb-1) solution for 3 minutes. The tip was then saturated with a blocking mAb isotype control monoclonal antibody (hereinafter referred to as blocking mAb) by dipping the antibody-captured biosensor tip into a well containing a solution of 200 μg / mL blocking mAb for 4 minutes. The biosensor tip was then subsequently dipped into a well containing a co-complexing solution of 25 nM hFXII and 1 μM of a second anti-human FXII monoclonal antibody (hereinafter referred to as mAb-2), which had been pre-incubated for 2 hours. Between each step of the experiment, the biosensor tip was washed in Octet HBS-P buffer. Real-time binding reactions were monitored during the experiment, and the binding reactions at the end of each step were recorded. Background binding correction was performed on the reaction of human FXII pre-complexed mAb-2 binding to mAb-1, and the competitive / non-competitive behavior of different anti-FXII monoclonal antibodies was compared and determined.
[0192] Table 7: Cross-competition of anti-hFXII / FXIIa antibodies for binding to human FXII
[0193]
[0194] Table 7 clearly defines the relationship of antibodies competing in both directions, regardless of the order of binding.
[0195] Example 5: Functional plasma assay to determine the inhibitory activity of anti-FXII / FXIIa antibodies
[0196] This example describes the inhibitory activity of the selected antibodies as determined by the following four functional plasma analyses: 1) activated partial thromboplastin time (aPTT), 2) prothrombin time (PT), 3) thrombin generation analysis (TGA) triggered by ellagic acid and 4) TGA triggered by tissue factor. The aPTT test evaluates all clotting factors of the endogenous and common pathways of the coagulation cascade by measuring the time to form a clot after the addition of calcium and ellagic acid, while the PT test evaluates all clotting factors of the endogenous and common pathways of the coagulation cascade after the addition of calcium and tissue factor. The TGA triggered by ellagic acid measures the rate and amount of thrombin generated via the endogenous and common pathways, while the TGA triggered by tissue factor measures the rate and amount of thrombin generated via the endogenous and common pathways.
[0197] Determination of aPTT
[0198] aPTT was measured on a Diagnostica Stago STart4 hemostasis analyzer in the following manner: a total of 50 μl of normal human plasma merged was added to a cuvette at 37°C. After 1 minute, PBS containing 5 μl of 2-fold serial dilutions of the test article (antibody or small molecule inhibitor) was added to the cuvette and incubated for 5 minutes. 50 μl of APPT-XL ellagic acid (Thermo Scientific) was then added and incubated for 300 seconds, followed by 50 μl of 20 mM calcium chloride (Thermo Scientific) to start the reaction. The measured clotting time of the test article concentration was normalized to the baseline (drug-free) plasma clotting time and plotted for the logarithmic molar concentration of the test article. Using Prism 5 software (GraphPad), nonlinear regression (4-parameter logic) analysis results were used to obtain the concentration of the doubling time.
[0199] PT determination
[0200] PT was determined on a Diagnostica Stago STart4 hemostasis analyzer in the following manner. A total of 50 μl of combined normal human plasma was added to a cuvette at 37°C. After 1 minute, PBS containing 5 μl of 2-fold serial dilutions of the test article (antibody or small molecule inhibitor) was added to the cuvette and incubated for 5 minutes. 100 μl of tissue factor (TriniCLOT PT Excel, Diagnostica Stago) was then added to start the reaction. The measured clotting time of the test article concentration was normalized to the baseline (drug-free) plasma clotting time and plotted for the logarithmic molar concentration of the test article. The results were analyzed using Prism 5 software (Graphpad) using nonlinear regression (4-parameter logic) to obtain the concentration of the doubling time.
[0201] TGA using ellagic acid
[0202] The thrombin generation profile was determined in a Thermo Scientific Hemker Thrombinoscope in the following manner: a total of 55 μl of combined normal human plasma was added to the wells of a microplate at 37°C. Then, 5 μl of PBS containing 2-fold serial dilutions of the test article (antibody or small molecule inhibitor) was added to the wells of the microplate and incubated for 30 minutes. 15 μl of APPT-XL ellagic acid (Thermo Scientific) was diluted in MP reagent, then added to the wells and incubated for 45 minutes. 15 μl of Fluo Flu Cal substrate (Staco Diagnostics Co., Ltd.) was then added, and the microplate was read immediately thereafter for 90 consecutive minutes. The measured real-time thrombin concentration values were plotted against time to obtain the thrombus map distribution of the test article used at each concentration.
[0203] TGA using tissue factor
[0204] The thrombin generation profile was determined in the Thermo Scientific Hemker Thrombinoscope in the following manner: a total of 55 μl of combined normal human plasma was added to the wells of the microplate at 37°C. Then, PBS containing 5 μl of 2-fold serial dilutions of the test article (antibody or small molecule inhibitor) was added to the wells of the microplate and incubated for 30 minutes. 15 μl of tissue factor PPP reagent (Sitago Diagnostics Co., Ltd.) was added to the wells and incubated for 45 minutes. Then 15 μl of Fluo Flu Cal substrate (Sitago Diagnostics Co., Ltd.) was added, and the microplate was read immediately for 90 consecutive minutes. The measured real-time thrombin concentration values were plotted against time to obtain the thrombus map distribution of the test article used at each concentration.
[0205] result
[0206] Dose response curves were generated to determine the effect of each drug on plasma aPTT and PT. The IgG4 isotype control antibody had no effect on aPTT or PT. Anti-FXII / FXIIa antibodies (mAb26036, mAb26048, mAb26049, and mAb26076) prolonged aPTT without increasing PT. The clinically approved anticoagulant FXa inhibitor, Apixaban, prolonged both aPTT and PT at μM concentrations. Comparator 1 prolonged aPTT without increasing PT. The efficiency of drugs that inhibit coagulation activity is expressed as an arbitrary "doubling time" concentration or C 2xt is the index, which is the drug concentration required to prolong the clotting time by more than twice the baseline value. These extrapolated C 2xt The values (ie, the curve that crosses the "doubling time line") are listed in Table 8.
[0207] Table 8: Drug concentrations required to increase clotting time more than 2-fold from baseline
[0208]
[0209] C 2xt = drug concentration required to increase clotting time by more than 2-fold of baseline (-) = no inhibitory effect on clotting time at doses up to 4 μM
[0210] Antibodies mAb26036, mAb26048, and mAb26049 reached C at ≤200 nM 2xt , while mAb26076 required 250 nM. None of the antibodies were found to double the PT clotting time at the maximum 4 μM tested. Apixaban reached aPTT C at 7 μM. 2xt , the concentration is greater than the PTC 2xtRequired concentration of 3.5 μM. Comparative 1 required 250 nM to achieve aPTTC 2xt , but did not reach PTC at 4 μM 2xt .
[0211] When plasma is triggered by ellagic acid or tissue factor, the antibody is evaluated for its ability to inhibit thrombin generation (i.e., the time extended by detecting thrombin = lag time, the reduction of thrombin peak and the reduction of the total amount of thrombin generated = endogenous thrombin potential). The isotype control has no effect on thrombin generation. The antibody shows a slight decrease in thrombin generation at 125nM, but significantly or completely inhibits thrombin generation at a concentration of ≥250nM, indicating that the antibody inhibits activation of the endogenous pathway, thereby preventing thrombin generation. Apixaban shows a dose-dependent decrease in thrombin generation, but cannot reach 2 times the lag time, or ETP or 1 / 2 of the peak value at the highest dose used (500nM). Comparator 1 shows a dose-dependent effect on thrombin generation, which is almost completely inhibited at 500nM. Thrombin generation triggered by tissue factor is not affected by the control isotype antibody. The antibody does not inhibit thrombin generation triggered by tissue factor. Apixaban dose-dependently inhibited thrombin generation when triggered by tissue factor. Comparative 1 had no effect on thrombin generation triggered by tissue factor. The concentrations of the test articles required to extend the lag time by two-fold and to reduce the thrombin peak and the total amount of thrombin generation by half when coagulation was activated by ellagic acid or tissue factor are summarized in Table 9.
[0212] Table 9: Drug concentrations required to delay and reduce thrombin generation
[0213]
[0214] (-) = No effect on thrombin generation up to 500 nM
[0215] The above results show that the exemplary antibodies inhibit thrombin generation by the intrinsic pathway without inhibiting the extrinsic pathway.
[0216] The present invention is not limited to the scope of the specific embodiments described herein. In fact, various modifications of the present invention, in addition to those described herein, will become apparent to those skilled in the art based on the foregoing description and the accompanying drawings. It is intended that such modifications fall within the scope of the appended claims.
Claims
1. A human antibody or antigen-binding fragment thereof that specifically binds to FXII / FXIIa, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region HCVR and a light chain variable region LCVR, wherein the heavy chain variable region comprises three heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3; and the light chain variable region LCVR comprises three light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the HCDR1, HCDR2 and HCDR3 consist of the amino acid sequences of SEQ ID NOs: 4, 6 and 8, respectively, and the HCDR1, HCDR2 and LCDR3 consist of the amino acid sequences of SEQ ID NOs: 12, 14 and 16, respectively.
2. The antibody or antigen-binding fragment thereof according to claim 1, having one or more of the following characteristics: (a) be a fully human monoclonal antibody; (b) Binds to the activating factor FXII / FXIIa; (c) with a dissociation constant (K) of less than 3.5 nM at 25 °C as measured by surface plasmon resonance analysis. D ) binds to FXII; (d) with a K of less than 17 nM at 37 °C as measured by surface plasmon resonance analysis. D Combined with FXII; (e) K of less than 5 nM at 25 °C as measured by surface plasmon resonance analysis D Binds to FXIIa; (f) K of less than 6.5 nM at 37 °C as measured by surface plasmon resonance analysis D Binds to FXIIa; (g) blocks thrombin generation by the intrinsic pathway at a concentration of less than 250 nM as measured by a functional plasma assay; and (h) Blockade of thrombin generation by the intrinsic pathway without blocking thrombin generation by the extrinsic pathway as measured by a functional plasma assay.
3. The antibody or antigen-binding fragment thereof of claim 1, comprising the HCVR and LCVR of SEQ ID NOs: 2 and 10, respectively.
4. A pharmaceutical composition comprising the isolated antibody or antigen-binding fragment thereof that binds to one or both of FXII and FXIIa according to any one of claims 1 to 3, and a pharmaceutically acceptable carrier or diluent.
5. An isolated polynucleotide molecule comprising a) a polynucleotide sequence encoding the HCVR of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3; and b) a polynucleotide sequence encoding the LCVR of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3. A vector comprising the polynucleotide sequence according to claim 5 .
7. A cell expressing the vector according to claim 6.
8. A method for producing an antibody or an antigen-binding fragment thereof that binds to one or both of FXII and FXIIa, comprising growing the cell according to claim 7 under conditions that allow production of the antibody or the antigen-binding fragment thereof, and recovering the antibody or the antigen-binding fragment thereof produced thereby.
9. Use of a therapeutically effective amount of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 3 or the pharmaceutical composition according to claim 4 in the preparation of a medicament for treating a subject suffering from or at risk of thrombosis.
10. The use according to claim 9, wherein the pharmaceutical composition is for preventive or therapeutic administration.
11. The use according to claim 9, wherein the antibody or antigen-binding fragment thereof or the pharmaceutical composition is for administration in combination with a second therapeutic agent.
12. The use according to claim 11, wherein the second therapeutic agent is selected from the group consisting of: anticoagulants, direct thrombin inhibitors, thrombolytic drugs, fibrinolytic drugs, antiplatelet drugs, anti-inflammatory drugs, antihypertensive drugs, a second anti-FXII / FXIIa antibody, lipid-lowering drugs and compression stockings.
13. The use according to claim 9, wherein the antibody or antigen-binding fragment thereof or the pharmaceutical composition is for subcutaneous, intravenous, intradermal, intraperitoneal or intramuscular administration.
